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Abstract of thesis entitled: 
Genetic variations in the pathway of sex steroids metabolism and the 
association with sex hormone concentration and liver cancer in 
Chinese men 
Submitted by Jiang Jieying 
for the degree of Master of Philosophy 
at The Chinese University of Hong Kong in June 2009 
Steady state blood sex steroid levels have been associated with various 
kinds of diseases. Such inter-individual variations of blood levels may be influenced 
by polymorphisms in genes encoding enzymes in the biosynthesis and metabolism 
pathways of sex hormones. Hepatitis B virus-related hepatocellular carcinoma (HCC) 
is hyperendemic in Southern China. Epidemiology studies indicated that the 
incidence of HCC in men was higher than that in women, and male predominance of 
hepatitis B virus related HCC was associated with serum levels of androgens. 
Therefore, genetic variations in the androgen metabolic pathway may predispose to 
HCC through effects on the blood sex steroid levels. 
In this project, single nucleotide polyporphisms (SNPs) of candidate genes 
(including SRD5A1, SRD5A2, HSD3B1, HSD17B2, AKR1C3, AKR1C4, AKRIDI, 
and CYP19A1) involved in sex steroid metabolic pathway were investigated. Part A 
study focused on their association with sex steroid concentrations in a 1402 Chinese 
elderly cohort. Part B study focused on genetic variations in relation to the risk of 
vi 
HCC. 
In the part A study, it was found that a few SNPs in SRD5A1, AKRl C4 
and CYP19A1 gene were associated with blood steroid concentrations. The 
genotype of rs 1173 8248 in SRD5A1 was significantly associated with circulating 
DHT/T ratio while the C-T-T haplotype on SRD5A1 could be a predictor for low 
DHT level. As for AKRl C4, it was found that the genotype rsl 7134607 was 
associated with androsterone level in a linear regression model. In addition, it was 
also observed that the G-A haplotype could be a risk haplotype for high 
androsterone level. As for CYP19A1, the SNP rs2899470 was significantly 
associated with serum E2, El levels and E2/T ratios. These results confirmed the 
role of genetic polymorphisms in sex steroid metabolic pathway on circulating sex 
steroid concentrations. 
In the part B study, it was found that compared with both population and 
HBV positive control group, SNP rsl 1738248 on SRD5A1 was significantly 
associated with risk of HCC. The C-T-T haplotype constructed by three SNPs in 
SRD5A1 (rs248807, rsll738248 and rs824811) could be a risk haplotype for HCC 
etiology. In addition, the SNP rs523349 (V89L) on SRD5A2 appeared to be 
associated with risk of HCC which was in keeping with previous findings. 
This study demonstrated the influence of genetic variations in sex steroid 
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metabolic pathway on (1) sex steroid levels and (2) predisposition for HCC among 
HBV carriers. The results provide additional support for the androgenic drive of 
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Chapter 1 Introduction 
1.1 Individual variations of blood sex steroid levels and their 
determinants 
1.1.1 Introduction to Sex steroids 
Sex steroid is the generic term for any natural or synthetic compound, 
usually a steroid hormone that stimulates or controls the development and 
maintenance of masculine characteristics in vertebrates by binding to androgen 
receptors. There are about 3 types of sex steroids, including androgens, estrogens and 
progestagens (Carrie J.Bagatell 2003). 
1.1.2 Androgens 
LL2,1 Types of androgens 
There are several types of androgens, including testosterone, the major 
androgen in men, 5a-dihydrotestosterone (DHT), its more potent biological 
metabolite, dehydroepiandrosterone (DHEA), androstenedione, androstenediol, 
androsterone, and other isoforms. Although there are many types of androgens, 
testosterone and DHT are two main androgen metabolites and the enzymes that play 
key role in androgen metabolism, and will be discussed in detail in late sessions 
(Carrie J.Bagatell 2003). 
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Testosterone, the major androgen in men, is necessary for fetal male 
sexual differentiation, pubertal development, the maintenance of adult secondary sex 
characteristics, spermatogenesis, and functions in many other tissues, including 
muscle and bone, and in the immune system. Testis is the source of more than 95% 
of the circulating testosterone in men. On the other hand, the adrenal cortex produces 
large amounts of the testosterone precursor steroids dehydroepiandrosterone (DHEA) 
and androstenedione. (Carrie J.Bagatell 2003) 
LI.2,2 Androgens plasma concentration and relative biological potencies 
In addition, DHT, androsterone, androstenedione, progesterone, and 
pregnenolone are also formed by testis in small amounts (Hammond et al. 1977). 
(Table LLl) 
Table 1.1.1 Plasma Concentration of Spermatic and Peripheral Venous Steroid (table 
adapted from (Larsen 2003) 
Steroid Concentration in Concentration in Decreased 
Spermatic Vein Peripheral Vein By ratio 
nmol/L ng/mL nmol/L ng/mL nmol/L ng/mL 
Testosterone 340-2000 100-600 8.7-35 2.5-10 40-57 40-60 
DHT 2-28 0.6-8.0 0.3-1.6 0.1-0.45 7-18 6-18 
Androsterone 1.4-38 0.4-1.1 0.5-14 0.15-0.4 3 3 
Androstenedione 3.8-42 1.1-12 1.4-3.8 0.4-1.1 3-11 3-11 
Progesterone 3.5-35 1.1-11 0.3-1.9 0.1-0.6 12-18 11.18 
Pregnenolone 3.5-35 1.1-12 0.9-3.0 0.3-1.0 4-12 4-12 
Although testosterone constitutes large portions of androgens in the plasma, 
DHT has more potent biological function than testosterone. DHT is 3 to 4 times more 
2 
potent than testosterone. Other androgens have very low potencies which are at least 
one order of magnitude lower than testosterone. (Table 1.1.2) 
Table LL2 Relative potency of androsens in plasma 
Dehydroepiandrosterone 
DHT Testosterone Androstenedione 
(DHEA) 
300 100 10 5 
1.1.2,3 Androgen biosynthesis and metabolism 
In the normal adult male, 95% of the testosterone circulating in the blood is 
synthesized in the Leydig cells in the testes, a total of 6-7mg per day. The remainder 
(5%) is produced in the adrenal glands (Carmthers 2004). 
Cholesterol is the primary precursor of testosterone. Activated by 
luteinizing hormone (LH), the mobilizing cholesterol is converted to androgens by a 
series of oxidative enzymatic steps. These stages progressively increase the 
androgenic activity of the molecule. Pregnenolone, produced in the mitochondria, 
will be converted to dehydroepiandrosterone (DHEA), or to a lesser extent 
progesterone, which are both weakly active. And then both metabolites could be 
converted to testosterone, which is fully active (Carmthers 2004). 
Testosterone serves as a circulating precursor or reserve for the formation 
of two types of active metabolites, DHT and estradiol, which in turn mediate many 
3 
androgen actions. (See Fisurel.LL marked with red colors). For example, the DHT, 
which is the metabolite of testosterone irreversible 5a-reduction process, is 
responsible for many aspects of male sexual development and vitalization. 
The finding that the 5a-DHT is the principle intracellular androgen in target 
tissues (Anderson & Liao 1968) and that DHT is more potent than testosterone in 
bioassay systems indicated that DHT mediate some androgen biological actions. The 
importance of DHT in normal androgen physiology has been demonstrated both by 
physiologic studies and by studies of human mutations in key enzymes that impair 
DHT formation (Thigpen et al. 1992; Wilson et al. 1993). 
DHT is further metabolized to 3a-androstanediol glucuronide (3a-diol G), in 
the liver, skin and kidney (Redmond 1995).Then, these water-soluble metabolites are 
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Figure 1.1.1 The biosynthesis and metabolism of androgenic steroids from 
cholesterol to active and inactive metabolites. Testosterone and its active product, 
DHT, are the most potent androgens formed. Enzymes mediating each metabolite are 
noted in yellow box. (Figure modified from (Larsen 2003; Redmond 1995)) 
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1,1.2.4 Testosterone transportation in plasma 
Testosterone is largely bound to proteins, mainly albumin and 
sex-hormone-binding globulin (SHBG) in the circulation (Larsen 2003). About 2% 
of testosterone is free (unbound), 44% is bound to SHBG, and 54% is bound to 
albumin and other proteins(Dunn et al. 1981).The fraction of testosterone bound to 
SHBG in serum is proportional the SHBG level. Albumin has about a 1000-fold 
lower affinity for testosterone than SHBG, but the concentration of albumin is much 
higher so that the binding capacities are similar. In addition, protein-bound 
testosterone can dissociate within the capillary bed so that the biologically active 
fraction is actually larger than the free fraction as estimated by equilibrium dialysis 
(Pardridge 1986). In fact, nearly all albumin-bound testosterone is readily converted 
to free testosterone for tissue uptake in vivo so that the bioavailable testosterone 
(BAT) is about half the total (Pardridge 1986).Changes in the availability of SHBG 
levels with disease or drug therapy influence the interpretation of total testosterone 
levels. Thus the measurement of the free and albumin-bound form of testosterone 
(BAT) is important for the detection of elevated serum testosterone levels 
(P.Redmond 1995). 
6 
LL2.5 Measurement of free testosterone 
For accurate assessment of androgen status in men and disease association, 
it is necessarily to measure free or bioavailable testosterone in blood as well. 
However, measurement of free testosterone by the golden method of equilibrium 
dialysis is impractical for routine laboratory practice (Ho et al. 2006). For the sake of 
rapid detection, some have proposed the measurement or calculation of BAT, which 
is the sum of albumin-bound and free testosterone. BAT corresponds well to 
measured free testosterone (Vermeulen et al. 1999). However, since BAT 
measurement requires precipitation of SHBG by ammonium sulfate, it is considered 
time-consuming by some clinical laboratories (Ho, Stoddart et al. 2006). In addition, 
the calculation of BAT by published equations with measured testosterone, album 
and SHBG levels has not been accepted by all (Diver 2006; Giton et al. 2006). 
One simple way to evaluate free testosterone concentration in serum is the free 
androgen index (FAI), which involves measurement of total testosterone and SHBG 
levels (Carter et al. 1983). The equation is 
FAI=100(total testosterone/SHBG) (Ho, Stoddart et al. 2006) 
The FAI ratio is the total testosterone concentration (nmol/L) to the concentration (or 
binding capacity) of SHBG (nmol/L). It is typically calculated on a molar/molar 
basis. FAI has no units. Since it is the simplest way to calculate serum free 
7 
testosterone concentration, it is often used as a substitute for free testosterone in 
epidemiology studies. However, it also has limitations. Because T production is 
regulated by gonadotropin feedback in men, SHBG changes which influence free 
testosterone concentrations will be compensated by autoregulation of testosterone 
production (Rosner et al. 2007). However, admitting those limitations, there is still a 
reasonable correlation between FAI and true biologically free testosterone level, and 
could be applied as an easy way to calculate serum free testosterone concentrations 
in clinical and epidemiology studies. 
1.1.2.6 The hypothalamus-pituitary-testicular axis and testosterone secretion 
The key regulator of testosterone synthesis and secretion is GnRH 
(Gonadotropin-Releasing Hormone), which is produced in neurons located diffusely 
throughout the anterior hypothalamus in primates. GnRH is released in bursts into 
hypothalamic portal blood and that each burst of GnRH is associated with an LH 
(Luteinizing Hormone) secretory pulse. (Caraty & Locatelli 1988) 
LH and FSH (Follicle Stimulating Hormone) are the primary pituitary 
hormones that regulate testicular functions. The acute administration of GnRH 
stimulates the release of both LH and FSH. Age and hormone status would influence 
the amounts of LH and FSH released in response to GnRH. Before puberty, the 
8 
secretion of FSH in response to GnRH is greater than that of LH. However, the 
situation will be reversed in an adult man (Marshall & Griffin 1993). 
In addition, testosterone regulates its own production by a negative 
feedback inhibition of LH secretion. In this way, it would prevent an unchecked 
testosterone production from the LH drive, which would bring undesirable side 
effects to body due to toxicity of overproduction of testosterone. Testosterone exerts 
this negative feedback effects by suppressing LH secretion and by downregulating 
gonadotropin subunit gene expression (Ishizaka et al. 1992). Most of testosterone 
feedback inhibition of LH in men appears to be via GnRH. (Finkelstein et al. 1991b) 
Follicle-stimulating hormone (FSH) secretion, as well as LH, is GnRH 
dependent, and both are suppressed after testosterone administration (Finkelstein et 
al. 1991a). In addition, FSH is negatively regulated by testicular inhibin-B (Burger & 
Robertson 1997). A schematic of the interrelationship between gonadotropin and 
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Fisure 1,1.2 A schematic of the hypothalamic-pituitary-testicular axis showing the 
interrelationship between GnRH, LH, FSH, testosterone and inhibin-B. 
1,L2.7Androgen action 
The intracellular androgen receptor dependent activating of androgen is 
mediated through DHT. The action of DHT is mediated by the androgen receptor 
(AR). AR is present in highest concentration in androgen target tissues such as the 
accessory organs of male reproduction and some areas of the brain (Wilson & 
French 1976). Tissues, such as liver, skeletal muscle (Snochowski et al. 1980), heart, 
vascular smooth muscle (McGill et al. 1980) and placenta express low level of 
receptor (McCormick et al. 1981). The active form of the androgen receptor is a 
homodimer formed by interacting sites in the N-terminal and C-terminal domains of 
the protein; the resulting homodimer interacts with other proteins (transcription 
factors) to form an active transcription regulatory complex (Culig et al. 2000). 
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DHT is the key ligand that binds to the AR to form an intracellular 
complex, which in turn binds to DNA, and induces transcription. It was found that 
only a small amount of DHT is required to trigger androgenic action in prostate 
cancer patients, perhaps because hypersensitive ARs in these patients (Culig, 
Hobisch et al. 2000). In the absence of androgen, non-androgenic hormones 
including estradiol, vitamin D, and insulin-like growth factors (IGFs) can also bind 
ARs, and produces androgenic action in prostate (Culig et al. 1996; Gnanapragasam 
et al. 2000). 
1.1.2.8 Androgen biological function and diseases in men 
Testosterone is the major sex hormone in men, and its biological functions 
in men have been demonstrated in various experiments. Men with androgen 
deficiency may exhibit reduced muscle bulk, strength and less favorable body 
composition compared with men with normal testosterone levels (Yeap 2009). In 
addition, decreased testosterone level may also be related to decreased bone health 
such as osteroporosis (Fink et al. 2006，Meier, 2008 #254). The metabolic syndrome, 
type 2 diabetes mellitus and heart attack in aging men are also observed to be 
associated with decreased testosterone levels (Laaksonen et al. 2004; Selvin et al. 
2007; van den Beld et al. 2003). Furthermore, androgen levels are closely associated 
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with various kinds of cancers such as prostate cancer (Hsing et al. 2002; Severi et al. 
2006) and hepatocellular carcinoma (HCC) (Kuper et al. 2001). 
1.1.3 Estrogen biological function and diseases in men 
Serum level of sex hormones have been associated with various clinical 
diseases such as prostate cancer (Hsing, Reichardt et al. 2002; Severi, Morris et al. 
2006), breast cancer (Key et al. 2002), and liver cancer (Kuper, Mantzoros et al. 
2001). 
Although testosterone is the major sex steroid in men, estrogens, both 
estradiol (E2) and estrone (El), also have important biological roles in the male sex 
as reviewed in both animal and human studies (Allen et al. 2003; Eriksson et al. 2008; 
Haiman et al. 2005; Key, Appleby et al. 2002; Sharp et al. 2004). Estrogen is 
particularly important in growth and maintenance of bone mineral density (BMD) 
(Allen, Reichardt et al. 2003; Eriksson, Lorentzon et al. 2008; Sharp, Cardy et al. 
2004; Vidal et al. 2000), skeletal muscle (Tiidus 2003), and hyperplasia of prostate 
glands and stroma (Risbridger et al. 2007). Recent prospective studies in a large 
cohort suggested beneficial effects of high endogenous E2 in various health 
outcomes, particularly among elderly men. Travison et al. showed that E2 correlated 
with bone strength at femur, and high E2 level also correlated with BMD (Travison 
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et al. 2009). In addition, a report recently demonstrated that older Swedish men with 
low E2 had increased risk of fractures (Mellstrom et al. 2008). E2 also had a 
protective effect on kidney against chronic kidney disease which had been found in 
both animal and epidemiological studies (Dubey & Jackson 2001; Dubey et al. 
2004). 
1.1.4 Factors influencing circulating sex steroid levels 
Many factors (both genetic and environmental) affect the production and 
thus circulating level of sex steroid levels. Age, BMI, drinking and smoking habits 
could exert influence on sex steroid levels in body. 
The levels of all components of serum testosterone decline as adult men 
age. (Carrie J.Bagatell 2003). Cross-sectional studies suggested that there was an 
age-related change between androgen level and age (Ferrini & Barrett-Connor 
1998; Gray et al. 1991)，and there were studies demonstrating that this decline was 
mainly in serum testosterone levels (Harman et al. 2001; Morley et al. 1997). Most of 
the data on testosterone levels and age were derived from studies in which the vast 
majority of men enrolled were Caucasian. Some smaller cross-sectional evaluations 
involving men of African-American or Asian descent (Perry et al. 2000) suggested 
that these ethnic groups might also support this age-related testosterone decline. 
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Serum dihydrotestosterone (DHT) levels, in general, did not change remarkably with 
age (Gray, Berlin et al. 1991). Serum estradiol (E2) rised slightly in men with 
age(Nieschlag et al. 1982). 
The age-related decline in serum testosterone is largely due to the 
decreased production by the testis, which could reduce testosterone production even 
under a maximum stimulation by luteinizing hormone (LH) (Nieschlag, Lammers et 
al. 1982). The hypothalamus also plays a role, which may due to an increased 
sensitivity to sex steroid negative feedback (Mulligan et al. 1997). Serum 
gonadotropin levels increase with age, but in most older men, even the testosterone 
level is quite low, gonadotropin levels are still within the normal adult male range 
(Gray, Berlin et al. 1991). In addition, a minor contributor to the T level decline may 
be related to the ratio ofbioactive to immimoreactive LH (Marrama et al. 1984). On 
the other hand, testosterone metabolism also slows down with aging, but it is not 
enough to compensate for the production decline. 
Studies suggested that excess body weight, measured by body-mass index 
(BMI) increased risk of prostate cancer and its progression (Ma et al. 2008; Maclnnis 
& English 2006). This effect was thought to be the consequence of alterations in 
sex hormone metabolism (Canby-Hagino & Thompson 2005). In addition, it has 
been suggested that obesity is associated with elevated serum estradiol levels owing 
14 
to peripheral conversion of testosterone to estradiol in adipocytes. In turn, estradiol 
leads to feedback inhibition of the pituitary-hypothalamic axis resulting in decreased 
free testosterone levels (Calle & Kaaks 2004). 
In contrast to the above factors, previous studies provide conflict results 
about the effects of cigarette smoking on testosterone levels in humans. The levels of 
testosterone could be lower (Briggs 1973), not changed (Klaiber & Broverman 
1988)，or higher in healthy smokers than in matched non smokers'(Field et al. 1994). 
It was reported that chronic alcohol consumption reduced plasma 
testosterone levels in men (Castilla-Garcia et al. 1987). Alcohol intake might exert 
effect on the both the hypothalamic-pituitary-adrenal (HPA) axis (Heinz et al. 1995) 
and the hypothalamo-pituitary-gonadal (HPG) axis (Schiavi et al. 1995). The 
underlying mechanisms may be explained by the suppression effect of alcohol on 
HPG axis through inhibition on the secretion of hypothalamic gonadotropin-releasing 
hormone (GnRH) and/or pituitary luteinizing hormone (LH) (Hiney & Dees 1991). 
In addition, alcohol also acted directly on the testes by reducing the testicular 
biosynthesis of testosterone (Orpana et al. 1990). 
LI,4,1 Genetic determinants affecting sex steroid levels 
Sex steroid levels alter dramatically in males during puberty. However, in 
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adulthood, it becomes stable and the between individuals variations in circulating 
levels of sex steroids could be largely attributed to genetic effect. Meikle et al. 
observed that familial factors accounted for 50% or more of the variation in plasma 
hormone levels in monozygotic twins (P<0.01) (Meikle et al. 1986). 
Many genes encoding enzymes are involved in the biosynthesis and 
metabolism pathways of sex hormones and they are naturally the candidate genes 
that might be responsible for the inter-individual variations of testosterone level. 
They include steroid 5 a -Reductase type I (SRD5A1), steroid 5 a -Reductase type II 
(SRD5A2), 3 /3-hydroxysteroid dehydrogenase (HSD3B1), 17/3-hydroxysteroid 
Dehydrogenase 2 (HSD17B2), 17/3-hydroxysteroid Dehydrogenase 3 (AKR1C3), 3 
a -hydroxysteroid dehydrogenase (AKR1C4), 5 /3 -Reductase(AKRl D1), aromatase 
(CYP19A1) which are critical enzymes in biosynthesis and transformation of sex 
steroids. They are shown in the Fisure 1.1.3 below. 
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Fisure 1.1.3 Steroidogenesis pathway showing the synthesis of androgen from 
cholesterol. Genes encoding for critical enzymes are marked with red color (Figure 
modified from (Chu et al. 2008; Larsen 2003; Redmond 1995) 
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1.2 Genetic variants in sex steroid metabolic pathway and 
hepatocellular carcinoma (HCC) 
1.2.1 Epidemiology of HCC 
Hepatocellular carcinoma (HCC) is the commonest primary cancer of the 
liver. HCC incidence is increasing in recent years and it has become the fifth 
commonest malignant tumor all over the world and the third leading cause of cancer 
related death, surpassed only by lung and stomach cancer (Organization). 
The estimated incidence of new cases is about 5000 000-1 000 000 per 
year, causing 600 000 deaths globally per year (Montalto et al. 2002; Parkin et al. 
2005; Sherman 2005). In addition, remarkable differences in incidence and etiology 
have been discovered between countries. Most cases of HCC occur in East Asia and 
sub-Saharan African (Llovet et al. 2003). In East Asia, the incidence is 99 per 100 
000 persons in Mongolia, 49 per 100 000 in Korea, 29 per 100 000 in Japan, and 35 
per 100 000 in China (Montalto, Cervello et al. 2002). Hong Kong and Thailand also 
have similarly high rates. Another region of high incidence rate is sub-Saharan 
African, particularly the western region of African. Italy, Spain, and Latin American 
countries are areas with moderately high incidence rate (11 cases/100 
000-20cases/100 000), and France, the United Kingdom, and the Federal Republic of 
Germany are areas at intermediate risk (5 cases/100 000-10 cases/100 000). United 
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States, Canada, and Scandinavia are areas which possess a relatively low incidence 
rate (less than 5 cases /lO 000) (Bosch et al. 2004; Montalto, Cervello et al. 2002). 
The large differences in the incidence rate may be due to ethnic, natural and 
environments factors. 
Although the incidence rate is relatively low in developed country, a rising 
tendency is observed in recent years (Di Bisceglie 2002; El-Serag & Mason 1999; 
Taylor-Robinson et al. 1999). Including the United States, this existing increase trend 
will likely to continue for some decades. The trend may be a result of a heavy burden 
of hepatitis B and C viruses infection which reached its peak in the 1950s to 1980s. 
On the other hand, in areas of some developing countries, the incidence of HCC has 
decreased, and the reason may be attributed to the introduction of hepatitis B virus 
vaccine (Bosch, Ribes et al. 2004). 
In addition, rates of liver cancer in men are 2 to 4 times higher than in 
women (Bosch, Ribes et al. 2004; Parkin, Bray et al. 2005) (Table 1.21. Figure 1.21} 
Not only males develop HCC more often than females, but once they develop the 
cancer, they also possess a worse survival rate and an elevated recurrence rate after 
the surgical treatment (El-Serag et al. 2001). 
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Table 1,21 Age standardized male to female incidence rates (per 100,000) of liver 
cancer in selected countries (table adapted from (Bosch, Ribes et al. 2004; Parkin, 
Bray et al. 2005)) 
Region Male Female Male to female 
m n a — 37.9 14.2 2.67 
Middle Africa 27.8 13.4 — 2.07 一 
Japan 23.1 7.9 一 2.92 
Eastern Africa m ^ 2.45 
South-eastern Asia 5J 
Southern Europe U ^ ^ 2.90 
^ b b e a n 一 8.2 4.5 “ 1.82 一 
Southern Africa 7.0 ^ 2.80 
Western Europe ^ ^ 
Eastern Europe ^ ^ 2.21 
Northern America 53 2.79 
Central America ^ ^ 1.00 
Western Asia — 4.6 2.0 — 2.30 
^ h e m Africa 4.2 2.2 — 1.91 
Australia/New Zealand 3.9 O 3.00 
South America 3.7 ^ 1.32 
Northern Europe 3A ^ 
^u th Central Asia 2.6 1.4 1.86 
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Age adjusted incidence rates of liver cancer per 100,000 
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Middle Africa p H B ^ H H ^ I H H i l bm^H •••••••^^H 27.8 
China • ^ — • — 1 — —137.9 
0 5 10 15 20 25 30 35 40 
Fisurel.2.1 According to increasing incidence of HCC, age standardized 
male and female incidence rates (per 100,000) of liver cancer in selected countries 
(figure adapted from (Bosch, Ribes et al. 2004; Parkin, Bray et al. 2005)) 
In Hong Kong, HCC is the third ranked cancer in male (10.4) and eighth 
ranked cancer in female (3.8). The number of cases registered was 1331 in male and 
414 in woman in 2006, with the 3.2 incidence ratio of male to female. The age 
specific death rate of liver cancer is increasing as the age increases. (Fisure 1,22) 
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Fisure 1.2.2 Age-specific death rate of malignant neoplasm of liver and intrahepatic 
bile ducts by sex, 2006. (Diagram adapted from 
http://www.healthvhk. gov.hk/phisweb/plain/en/healthy facts/disease burden/mai or_ 
causes death/cancers/liver cancer/showlargel .html 
1.2.2 Etiological factors of HCC 
Several factors have been found to be important in carcinogenesis of HCC. 
They are hepatitis B and C virus infection, aflatoxin exposure, and genetic factors. 
Chronic infection with the hepatitis B virus (HBV) is the most important 
risk factor for development of hepatocellular carcinoma (HCC). The pathogenesis of 
cancer in HBV infection has been extensively studied, and multiple factors could be 
contributed to the HCC development. Chronic inflammation and cytokines could 
lead to the fibrosis formation, liver cell proliferation and malignant transformation, 
which are important in the HCC development (Brechot 2004). In addition, it was 
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shown that HBV DNA randomly integrated into liver cell genome of patients during 
liver cell proliferation, thus they might be associated with chromosomal instability, 
and thus inducing genome rearrangement (Aoki et al. 1996). The expression of 
Hepatitis B X gene, truncated PreS2/S, and the newly discovered hepatitis B spliced 
proteins (HBSP) all modulated cell proliferation and viability (Brechot 2004). On the 
other hand, the etiology and pathogenetic mechanisms of persisting HBV infection in 
patients without detectable hepatitis B surface antigen (HBsAg) in the serum (often 
called occult HBV infection) has been less certain and debated for many years. 
(Brechot et al. 2000; Brechot et al. 2001; Pollicino et al. 2004; Torbenson & 
Thomas 2002). 
HCV is the most important risk factor for HCC in developed countries of 
western European and North America, since epidemiologic studies have shown up to 
70% of these patients with HCC have anti-HCV antibody in the serum(Bruix et al. 
1989; Montalto, Cervello et al. 2002). However, in contrast to HBV, HCV does not 
integrate into host DNA. Instead, it is likely that the HCC- host interactions lead to 
inflammatory response to the virus. Direct host defense effects of HCV were induced 
by several proteins, including the structural core protein and the nonstructural 
proteins NS3 and NS5, and they interfered with p53-mediated cell apoptosis (Anzola 
2004). 
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Alatoxin B1 (AFBl) is produced by a fungus of the genus, Aspergillus spp, 
in Asia and sub-Saharan Africa where climate and storage techniques favor the 
growth of this fungus and it is a common contaminant of foods (Gomaa et al. 2008). 
Areas with high exposure of AFBl coincide with areas with a high prevalence of 
HCC. It has been observed that areas with a high prevalence of HCC and high 
aflatoxin intake also correspond to areas with endemic HBV infection (Groopman et 
al. 1996). HBV infection and aflatoxin intake seem to have synergic effect on the risk 
of HCC. It was found that the risk of HCC increased by 3 fold in aflatoxin alone, by 
7 fold in HBV infection alone, while 59 fold in the combination of both risk factors 
(Ross et al. 1992). 
1.2.3 The male predominance in HCC 
As mentioned, HCC develops more frequently in men than in women. It 
is universally observed that the incidence rate of HCC in men was about 2-3 fold 
compared with women (Organization). 
About a decade ago, studies focused on the carcinogen of HCC such as 
HBx gene and HCV vims on animal models found that transgenic male mice were 
more likely to develop HCC and died much earlier than female mice (Kim et al 1991; 
Moriya et al. 1998). Some experiments also found that after the carcinogen treatment, 
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male mice had a larger number of hepatic foci, suggesting that androgens may 
increase the rate of focus formation in animals (Katayama et al. 1984; Poole & 
Drinkwater 1996). Furthermore, some studies demonstrated that castration reduced 
the incidence of tumor in carcinogen induced liver cancer on male mice (Lindhe et al. 
1990; Vesselinovitch et al. 1980). The male predominance in animal models has been 
attributed to the cancer promoter effect of androgen and a protective role of estrogen 
(Yamamoto et al. 1993). Dehydroepiandrosterone (DHEA), a weak androgenic 
steroid produced by adrenal, induced liver tumour in rats, and a carcinogen effect in 
different sex had been observed (Rao & Subbarao 1998). 
In clinical study, high serum testosterone levels have been suggested to be a 
risk factor in the HCC development. In 1993，Yu et al. first described a positive 
association between serum testosterone levels and risk of HCC in a nested case 
control study in Taiwan, where hepatitis B represents a major causative agent. The 
relative risk of HCC for men with higher tertile of testosterone levels was 4.1 
compared with those with middle or lower tertiles (P = 0.016，95% CI = 1.3-13.2) 
(Yu & Chen 1993). This positive association was subsequently observed in a 
replicated study in Shanghai, but the association became no more evident after the 
adjustment of serum HBV status (Yuan et al. 1995). In 2000, Yu et al. pointed out 
further that elevated testosterone was more strongly associated with early-onset of 
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HCC (OR = 4.67; 95% CI = 1.41--15.38) than late-onset disease (OR=1.64; 
95%CI=0.81-3.32). In addition, they proposed that not only testosterone levels, but 
also CAG repeats on the androgen receptor gene, may be associated with an 
increased risk of HBV-related HCC in men (Yu et al. 2000b). However, clinical trials 
of various hormonal therapies had been found largely ineffective in treatment of 
established cases of HCC (De Maria et al. 2002; Pignata et al. 1998). 
1.2.4 Genetic predisposition to HCC 
Other than environmental factors, genetic polymorphisms have also been 
widely studied in HCC. Segregation analysis of Chinese families with HCC indicated 
that a model of recessive inheritance was involved with at least one major gene (Cai 
et al. 2003; Yu, Cheng et al. 2000b). Searching for predisposition genes by means of 
a whole genome linkage scan is difficult as the mortality rate of HCC is high thus 
limits recruitment of affected family members. However, an alternative approach to 
detecting predisposition genes is genetic association study which has been carried out 
to investigate candidate genes involved in various cellular pathways. Positive 
associations have been found between HCC and genes encoding for phase I and 
phase II detoxification enzymes (Huang et al. 2003; Sun et al. 2001). In addition, the 
association between other candidate genes involved in cell cycle regulation and DNA 
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repair and risk of HCC have also been reported (Yu et al. 2003; Zhang et al. 2002 ). 
Since genetic variation may cause protein expression level change hence 
leading to interindividual variation in a certain protein circulating level, therefore 
genetic polymorphisms may be suspected to cancer predispositions. 
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Chapter 2 Part A study： Genetic variations in sex steroid 
metabolic pathway and association with sex 
steroid levels 
2.1 Introduction 
2.1,1 Candidate genes association with sex steroid levels 
Serum level of sex hormones have been associated with various clinical 
diseases such as prostate cancer (Hsing, Reichardt et al. 2002; Severi, Moms et al. 
2006), breast cancer (Key, Appleby et al. 2002), and liver cancer (Kuper, Mantzoros 
et al. 2001), and they also associated with various intermediate traits. However, there 
was limited understanding of the underlying determinants of circulating steroid 
levels. 
Sex steroid levels in the circulation alter dramatically in males during 
puberty. However, in adulthood, it has been demonstrated that inter-individual 
variations in circulating levels of sex steroids could be largely attributed to genetic 
effect. Meikle et al. observed that familial factors accounted for 50% or more of the 
variation in plasma hormone levels in monozygotic twins (P<0.01) (Meikle, Bishop 
etal. 1986). 
Many enzymes are involved in the biosynthesis and metabolism pathways of 
sex hormones, including steroid 5 a -Reductase type I (SRD5A1), steroid 5 a 
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-Reductase type II (SRD5A2), 3/3-hydroxysteroid dehydrogenase (HSD3B1), 17 ^ 
-hydroxysteroid Dehydrogenase 2 (HSD17B2), \1 ^ -hydroxysteroid Dehydrogenase 
3 (AKR1C3), 3 a -hydroxysteroid dehydrogenase (AKR1C4), 5 yS 
-Reductase(AKRlD1), aromatase (CYP19A1) are critical enzymes in biosynthesis 
and transformation of sex steroids which are shown in the Fisure 1.1.3 before. 
These genes are candidate genes involved in sex steroid metabolic pathway. 
Polymorphisms in these genes may result in alteration of enzyme" activity and thus 
exert an effect on sex steroid levels. As a result, I proposed to study these genes 
involved in sex steroid metabolic pathway to investigate whether genetic variations 
are associated with sex hormone levels in the circulation. 
2.1.2 Genes involved in androgen metabolism 
2.1.2.1 SRD5A 
In human bodies, the male phenotypes are dependent mainly on two 
androgens: testosterone (T) and dihydrotestosterone (DHT), both of which are 5 a 
-reductase isozymes that transform T into its more potent biological form, DHT. 
Russell and Wilson (Russell & Wilson 1994) discovered that each of these two 
genes contains 5 exons and share a 50% similarity in nucleotide sequences. The 28-
to 29kDa enzyme proteins are localized in the endoplasmic reticulum and across the 
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nuclear membrane, where it utilizes Tas a substrate with NADPH as a cofactor 
(Russell & Wilson 1994). The gene encodig SRD5A1 is located on chromosome 5 
at 5pl5.5 (Jenkins et al. 1991), while that locating for SRD5A2 is located on 
chromosome 2 at 2p23 (Chu, Reichardt et al. 2008). Differences between SRD5A1 
and SRD5A2 mostly lie in their physical and chemical properties, including optimal 
pH, sensitivity to 4-azasteroid inhibitor finasteride, tissue expression level, function 
and so on. First, SRD5A1 maintains a high enzymatic activity across a broad pH 
range from 6.5 to 8.0, while SRD5A2 has a narrower acidic pH (5.0) optimum. 
Second, SRD5A1 is relatively insensitive to the finasteride while SRD5A2 can be 
strongly inhibited by finasteride (Harris et al. 1992). In tissue expression study, 
Thigpen reported that SRD5A1 was found largely in non reproductive tissues such as 
skin and liver, whereas SRD5A2 is located predominantly in the male reproductive 
tissues including seminal vesicles, epididymis, and prostate (Thigpen et al. 1993). In 
addition, the expression of SRD5A2 is believed to be responsible for the sexual 
organ growth while the expression of SRD5A1 in skin cells is thought to be crucial 
for male pattern baldness, hirsutism and acne, as well as steroid metabolism in the 
liver(Poletti et al. 1998). 
2d,2,2HSD3Bl 
The 3 3 -hydroxysteroid dehydrogenase play an important role in androgen 
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metabolism; they catalyze androstenedione production, irreversibly inactivate DHT, 
and hence regulate DHT levels (Roberts et al. 2006). The HSD3B1 gene, located on 
chromosome lpl3.1, encodes for enzyme 3 ^ -hydroxysteroid dehydrogenase 
activity (Park et al. 2007). In humans, the HSD3B1 is mainly expressed in placenta 
and peripheral tissues, such as prostate, breast and skin (Wang et al. 2007). 
2.1.2.3 HSD17B2 
Distributed among many extraglandular tissues and liver, the \1 ^ -HSD 
type 2 isozyme catalyzes the conversion of the inactive C19-steroid androstenedione 
to the biologically active androgen, testosterone (Moghrabi et al. 1998). In addition, 
it is also responsible for the oxidation (inactivation) of estradiol to estrone (Olson et 
al. 2007). 
2J.2.4AKR1C3 andAKRlC4 
By sequence analysis, Khanna et al. found that the AKR1C4 and AKR1C3 
genes contain 9 exons and span 15 to 20 kb. The 9 exons have the identical sizes and 
boundaries in both genes (Khanna et al. 1995). 
Located in 10pl5-pl4, AKR1C3 has been detected in multiple tissues 
including prostate, liver, small intestine, colon, lung, and kidney (Lin et al. 1997). 
AKR1C3 highly efficiently converts active androgens androstenedione to 
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testosterone, and less efficiently inactivates DHT to its metabolic form, 3-alpha 
androstanediol (Roberts, Bergstralh et al. 2006). 
Specifically expressed in liver, the 3 a -hydroxysteroid dehydrogenase 
(AKR1C4) could transform the most potent natural androgen, DHT, into 
5-alpha-androstan-3 -alpha, 17-beta-diol (3 a -diolG), a metabolite with much lower 
activity (Dufort et al. 2001). 
In addition, AKR1C4 also work in together with 5 yS -reductase (AKRIDI) 
in bile-acid biosynthesis and in the steroid hormones metabolism to convert DHT to 
its metabolic product, androsterone(Penning et al. 2003). 
2.1.2.5 AKRIDI 
Located in 7q32.33, AKRIDI is specifically expressed in liver, and plays 
its crucial role together with SRD5A in converting testosterone to its more potent 
biological form, DHT. In addition, 5 /S -reductase also has vital synthetic roles in 
bile-acid synthesis (Palermo et al. 2008). 
2.1.3 Genes involved in estrogen metabolism 
2丄3.1 CYP19A1 
The CYP19A1 gene, located on chromosome 15q21.1, encodes for the key 
steroidogenic enzyme aromatase. The aromatase plays important role in catalyzing 
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the irreversible conversion of both testosterone (T) to estradiol (E2) and 
androstenedione to estrone (El). In addition, it also catalyzes the reversible 
conversion of both T and androstenedione, El and E2 (Anand 1996; Eriksson, 
Lorentzon et al. 2008). Aromatase is widely distributed in the gonads and in the 
extragonadal organs and tissues, including the breast, prostate, liver, muscle and 
adipose tissues (Anand 1996). 
2,13,2 Other genes involved in estrogen metabolism 
There are other genes involved in estrogen metabolism and biosynthesis. 
CYPIBI catalyzes the conversion of estradiol to the 4-OH catechol estrogen 
metabolites. COMT converts a methyl group to the catechol estrogens, and this 
conversion makes estrogens more water soluble thus enhances their excretion. By 
converting pregnenolone and progesterone to precursors of androgen and estrogen, 
CYP17 is responsible for the early stage of estrogen biosynthesis (Greenlee et al. 
2007). 
2.1.4 Association of sex steroid related genes and blood 
concentrations of sex steroid levels 
2d,4.1 Genes involved in androgen metabolic pathway and association with sex 
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steroid levels 
The study on the association between sex steroid levels and SRD5A2 gene 
has generated slight different association results in different ethnic groups. The 
SRD5A2 V89L polymorphism is caused by a G to C transversion that results in the 
substitution of valine for leucine at codon 89 (denoted the L allele). The V89L L/L 
(leucine homozygotes) genotype was found to have a lower mean serum sex steroid 
metabolite 3 a androstanediol glucuronide (3 a -diolG) concentration among Asian 
men. Such results suggested that the Leucine allele may reduce 5a-reductase activity 
(Makridakis et al. 1997). In addition, Makridakis et al. also found no association 
between SRD5A2 V89L and serum testosterone concentration among Asian men 
(Makridakis, Ross et al. 1997). On the other hand, two relatively large scale studies 
carried out by Allen et al. and Hayes et al. observed different findings on associations 
in SRD5A2 V89L and testosterone levels among European men. The study carried 
on by Allen et.al involved 621 British men in 2001 indicated that SRD5A2 V89L was 
not associated with low 3 a -diolG concentration, but instead the L/L genotype of 
SRD5A2 V89L was significantly associated with 12% lower testosterone 
concentrations (Allen et al. 2001), which contradicts with Hayes et.al who suggested 
no association between V89L and serum testosterone level(Hayes et al. 2007). 
Although these studies showed association with different metabolites, the leucine 
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allele was consistent in term of association with a lower androgen level. 
Not only V89L, but also A49T, which replaces the normal alanine residue with 
threonine at codon 49 in SRD5A2 was found to be associated with sex steroid levels. 
Allen et al. suggested in 2003 that A49T predisposed to a lower 3 a -diolG 
concentration in British men. The men who possessed one or two copies of the 
variant T allele (ie. carriers or homozygote of the mutant) in the A49T polymorphism 
appeared to have significantly lower 3 a -diolG concentration compared with men 
who were homozygous for the wild-type allele (p = 0.0003) (Allen, Reichardt et al. 
2003). This finding was confirmed by a study carried on by Hayes et al. in 2006, 
which including 827 cases and 736 controls from an Australian population to detect 
association between SRD5A2 the risk of prostate cancer, and found that SRD5A2 
A49T variant could be a predictor for lower circulating 3 a -diol G levels (pO.OOOl) 
(Hayes, Severi et al. 2007). 
In addition, SRD5A1 polymorphisms were also found to associate with DHT/T 
ratio. The homozygous A alleles on SRD5A1 Hinfl SNP was indicated to be 
significantly associated with higher serum DHT/T ratio (p=0.009) (Ellis et al. 2005). 
However, there was no association with the DHT or T levels directly. 
Some studies reported an association between AKR1C3 and sex steroid levels. 
Rizner et al. indicated in 2006 that AKR1C3 might determine progesterone and 
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estrogen levels together with AKRl CI (Rizner et al. 2006). In 2007，Jakobsson etal 
observed that the Glu77Gly polymorphism in AKRl C3 was associated with lower 
testosterone levels in serum (Jakobsson et al. 2007). 
2,L4,2 Genes involved in estrogen metabolic pathway and association with sex 
steroid levels 
Some studies have found that aromatase, which is responsible for 
converting testosterone (T) to estrdiol (E2) and androstenedione to estrone (El), 
encoded by CYP19A1, was associated with blood E2 levels among women (Dunning 
et al. 2004; Haiman et al. 2007). However, lack of association was also found in 
others (Travis et al. 2004). 
On the other hand, there is scarce data about the impact of genetic 
variations in CYP19A1 on E2 levels in men. A study in the elderly population, 
reported an association between a TTTA repeat polymorphism in intron 4 of the 
CYP19 gene and E2 levels in men, but sample size was rather small (N=300) 
(Gennari et al. 2004). 
Eriksson et al. carried out a large scale study (including 3 groups of men, 
N=5527) to identify genetic variations in sex steroid-related genes which were 
associated with serum levels of E2 and T in men (Eriksson, Lorentzon et al. 2008). 
Upon examination of all 604 single nucleotide polymorphisms (SNPs) in 50 sex 
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steroid-related candidate genes, the SNP rs2470152 in intron 2 of the CYP19A1 gene 
showed the most significant association with serum E2 levels (p=2xl0"^). In addition, 
rs2899470 in the intron 10 of the CYP19A1 gene, also exhibited a modest 
association with an unadjusted p-values of p<0.001. And the association with the 
SNP rs2470152 was replicated, in two other cohort of Swedish and US elderly men, 
with a combined p-value for all three cohorts of 2 x 10"^ "^ (Eriksson, Lorentzon et al. 
2008). However, these latest findings have not been replicated in other populations. 
Therefore, these two SNPs are also included in my list of candidate polymorphisms 
in this study. 
2.1.5 Aims of the study (Part A) 
Many enzymes are involved in the biosynthesis and metabolism pathways 
of sex hormones. Previous studies have shown that some genes involved in sex 
steroid metabolic pathway could be predictor for sex steroid levels (Ellis, 
Panagiotopoulos et al. 2005; Eriksson, Lorentzon et al. 2008; Gennari, Masi et al. 
2004). Polymorphisms in these sex steroid related genes may result in alteration of 
enzyme activity and thus exert an effect on sex steroid levels. As a result, we 
proposed to study these genes involved in sex steroid metabolic pathway to 
investigate whether genetic variations are associated with sex hormone levels. 
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Hypothesis: Genetic polymorphisms in the sex steroid metabolic pathway 
are associated with sex steroid level in the circulation. 
Objective: 1 .Replication study of association between CYP19A1 gene and 
sex steroid levels in order to reveal whether this association exit among Chinese men 
population. 2. Detect the associations between other genes involved in androgen 
metabolic pathway and sex steroid levels in Chinese men population. 
2.2 Materials and methods 
2.2.1 Study subjects and biological samples 
A MrOs (HK) cohort of two thousand ambulatory Chinese men living in the 
community, aged 65 years and above, were recruited by posting advertisements at 
community centers for the elderly and housing estates in Hong Kong since 2001. All 
subjects were invited to the School of Public Health of the Chinese University of 
Hong Kong, where their body weight (kg), height (cm), and body mass index (BMI) 
were measured. Peripheral blood samples were collected for DNA extraction. Blood 
steroid levels of 1402 men were available for analysis. A questionnaire was also 
administrated to collect information regarding their age, smoking and drinking habits, 
and other life-style factors. All participants gave written informed consent, and the 
study has been approved by the Clinical Research Ethics Committee of the Chinese 
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University of Hong Kong. 
Serum samples were collected in the morning after an overnight fast, and 
serum was stored at -80°C after separation until assay. Method was described in the 
previous study (Eriksson, Lorentzon et al. 2008).The serum sex steroid levels were 
quantitated using a gas chromatographic negative ionization tandem mass 
spectrometry (GC/NCI/MS/MS) as part of an international collaboration (Laboratory 
of Molecular Endocrinology and Oncology, Laval University, Quebec, Canada) 
(Assay properties on testosterone and estrogens were as follows: SHBG , limit of 
detection 0.2ninol/l, intra-assay CV 5.6%, inter-assay CV:6.5%.T, limit of detection 
0.05ng/ml, intra-assay CV 2.9%, interassay CV 3.4%; E2, limit of detection 2.00 
pg/ml, intra-assay CV 1.5%, interassay CV 2.7%; El, limit of detection 8.00pg/ml, 
intra-assay CV 1.8%, interassay CV 1.7%)(Eriksson, Lorentzon et al. 2008). 
Genomic DNA was extracted from peripheral blood samples using 
commercial extraction kit according to manufacture's instruction (GE Healthcare, 
USA). The extracted DNA samples were stored at -80°C before genotyping. 
2.2.2 TagSNP selection 
Data of all Han Chinese (CHB) SNPs within the genes involved in sex 
steroid metabolic pathway were obtained from the International HapMap Phase II 
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project (release #21 a/phase II, Mar08). Using a spectral decomposition algorithm, a 
total of two to four factors for each gene were identified, depending on length and 
composition of that gene. Factors correspond to tagging SNPs in each gene that 
delineate the overall genetic variation in the genomic region, including coding and 
non-coding sequences of the gene and results of 7 genes were listed in Table 2.21. 
All SNPs with minor allele frequencies of at least 5% in Asians were included by the 
algorithm (Home & Camp 2004; Lin & Altman 2004; Meng et al. 2003). 
Table 2.2.1 Gene component analysis and SNP pick up result 
Component % of Cumulative Representative 
variance % SNP in the 
component 
SRD5A1 1 45.15 45.15 rs248807 
2 35.86 81.01 rsl 1738248 
3 8.41 89.48 rs824811 
SRD5A2 1 50.86 50.86 rs3731586 
2 44.01 94.95 rsl 2470143 
HSD17B2 1 35.43 35.43 rsl364286 
2 22.73 58.15 rs2966241 
3 12.83 70.98 rs2955162 
4 7.86 78.84 rsl364283 
HSD3B1 1 52.54 52.54 rsl2022215 
2 32.86 85.43 rs879332 
AKR1C3 1 49.56 49.56 rs4881400 
2 43.72 93.28 rsl 1252940 
AKRlDl 1 73.19 73.19 rsll982192 
2 15.80 95.00 rs2306845 
AKR1C4 1 73.50 73.50 rsl334473 
2 90.00 rsl7134607 
Therefore, by the selected set of tagSNPs，the covered percentage of 
variance ranged from 78.98% in HSD17B2 gene to 95% in AKRIDI gene. 
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In addition, two candidate SNPs of CYP19A1, rs2470152 and rs2899470 
were selected to replicate the findings in the recently published Caucasian study 
(Eriksson, Lorentzon et al. 2008), and it also noted that they represented tagSNPs of 
the gene and corresponded to the common haplotypes of the region. 
2.2.3 Genotyping of tagging SNPs 
A melting temperature (Tm)-shift allele-specific genotyping method 
performed in single-tube PGR was used (Germer & Higuchi 1999; Wang et al. 
2005). For each SNP, two allele-specific primers carrying additional 5’ GC sequence 
were designed. Typically, a long 14-bp 5' GC sequence 
(5'-GCGGGCAGGGCGGC-3') was added to one of the allele-specific primer, while 
a short 5' 8-bp GC tail (5'-GATTACCG-3') was attached to the other allele-specific 
primer. By attaching GC tails of different lengths onto the 5, end of each pairs of 
allele-specific primers, genotypes at the SNP could be identified from the melting 
profile of the PGR products, as the different GC 5’ tail will generate a 3-4�C 
difference in Tm between the allele-specific PGR products (Germer & Higuchi 
1999; Wang, Chuang et al. 2005). One common complementary primer located 
around 20bp downstream from the SNP was also designed for each SNP. Known 
LCL (lymphoblastoid cell line) of 45 Chinese men (data obtained form HapMap) was 
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used as positive control to distinguish 3 different peak shapes. The ddHzO was used 
as negative controls 
All PCRs were set up using the Biomek® 2000 robotic system (Beckman Coulter, 
Fullerton, CA, USA). The PCR master mixture was prepared with a total volume of 
12.5 and contained 25ng of genomic DNA, 0.4mM of each dNTP, 0.2X SYBR 
Green I (Invitrogen)，10% DMSO, Ix TaqGold buffer and 0.6U Ampli TaqGold 
polymerase (Applied Biosystems, USA). DNA amplification was performed by 
initially heating the PCR reaction mixture 95°C for 15 min to activate the polymerase, 
followed by 35 cycles of denaturation for 20 s at 95°C, 1 min at 60°C for annealing, 
and 30 s at 72°C for elongation. Melting curve analysis was monitored on the 
LightCycler® 480 Real-Time PCR System (Roche Applied Science). Using the 
onboard software (LightCycler(D480 software, vl.5) the melting curve data were 
obtained by detecting the fluorescence intensity of the PCR products in a 
denaturation ramp from 60°C - 90°C at 0.5°C/s temperature increment. TagSNPs, 
primers and PCR conditions are shown in Table 2.2.2-2,2,9. A typing Melting profile 











































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Mel t ing P e a k s 
2.11 & //:\ 
Homozygous allele^^ A^ 
J ::二 J l / H 0 m 0 Z y 9 0 U S a , , e l e s 
Jf 111& Heterozygous allel^ f ^ ^ ^ f t 
_ ^ i i l 
• . 一 ： 一 丄 
60 65 70 75 80 85 
Temperature (*CJ 
Figure 2.2.1 Melting profiles of genotypes. The green peaks represent homozygous 
alleles with low melting temperature (Tm), while the blue peaks represent 
homozygous alleles with high Tm. The double red peaks represent heterozygous 
alleles. 
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2.2.4 Genotyping methods comparison 
In my study, I used a melting temperature (Tm)-shift allele-specific 
genotyping method to genotype my samples. There are other genotyping methods, 
such as RFLP (restriction fragment length polymorphism), TaqMan and sequencing. 
The comparisons of these methods are listed in the Table 2.2.4.1. 
Table 2.2.4.1 Comparison of different genotyping methods 
Melting RFLP TaqMan Sequencing 
Time About 3 hours About 10 hours About 3 6-8 hours 
hours 




Main Specificity relatively Time consuming, Expensive Expensive 
Limitations lower compared with Exposure to toxic Time consuming 
TaqMan and sequencing reagents 
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2.2.5 Statistics 
Genotype distribution of candidate genes polymorphisms were assessed for 
deviations by Hardy-Weinberg Equilibrium (HWE) with x test. Differences in serum 
levels of sex steroids and SNPs in candidate genes were evaluated using ANOVA of 
standardized residual after adjustment of age and BMI, while represented the age and 
BMI adjusted steroid levels. If SNP genotypes differences were found in one-way 
ANOVA test, the associations of SNPs with sex steroid levels were examined in 
multivariate linear regression models including demographic, life style factors and 
SHBG. If SNPs were found to be significantly associated with sex steroid levels, the 
study population was divided into 3 groups according to the tertile levels of sex 
steroid levels for haplotype analysis. For a categorical analysis and "haplotype 
association", subjects with highest sex steroid levels within the high tertile were also 
compared to those with levels in the low tertile. All statistical analyses were carried 
out using SPSS 15 for Windows (SPSS Inc., Chicago, IL, USA), and results were 
two tailed and conducted at the 5% significance level. 
To determine the haplotypes association with high or low sex steroid levels, 
Haploview 4.1 (Barrett et al. 2005) was used to infer haplotypes using an accelerated 
expectation maximization algorithm in the tertile group analysis. 
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2.3 Results 
2.3.1 Characteristics of study population 
The demographic and clinical data of the study participants were 
summarized in Table 2.3.1.The study cohort consisted of 1402 Chinese men with 
available sex steroid levels. The mean age was 72.5±5.0 years. Mean BMI was 
23.4±3.1, and 64.0% of them have smoking habit and 72.5% of them were alcohol 
drinkers. The serum sex steroid levels of the whole sample were presented in the 
table as mean士SD. 
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Table 2.3.1 Characterization of study subjects 
Variables Subjects (N=1402) 
Age(yr) 72.5 土 5.0 
Body Mass Index(BMI) 23.4 ± 3 • 1 
Smokers 897 (64.0%) 
Alcohol drinkers 1016 (72.5%) 
Serum sex steroids 
E2 (pg/ml) 24.5 土 14.5 
El (pg/ml) 34.4 ±12.7 
T (ng/ml) 5.5 ±2.1 
0 . 4 7 土 0 . 2 2 3 
DHT (ng/ml) 
SHBG(nmol/l) 51.2 ±20.4 
Data are presented as means土SD for continuous variables, and frequency (percentage) 
for categorical variables. 
2.3.2 Replication study for the association of CYP19A1 
2.3.2.1 Association of the SNP rs2470152 and rs2899470 with serum estrogen and 
testosterone levels 
The genotype and allele frequencies for the 2 SNPs in this replication study 
were shown in Table 2.3.2.1.1, Genotype frequencies of both SNPs did not deviate 
from HWE (p>0.05). The univariate association of these SNPs with serum steroid 
levels was shown in Table 2.3.2.1.2, For rs2470152, the E2/T ratio was significantly 
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higher in the group of CC genotype compared with TT genotype (p=0.011). For 
rs2899470, the E2, El and E2/T ratio were all significantly higher in GG genotype 
compared with GT and TT genotype (p<0.001, respectively, indicated in Figure 
2.3.2.1), The SNP rs2899470 in CYP19A1 was significantly associated with serum 
E2, El and E2/T levels after the adjustment of confounding factors such as age, BMI, 
smoking and drinking status, and serum sex hormone binding globulin (SHBG) level. 
rp<0.001. Table 2.3.2.1.3) However, the SNP rs2470152, which showed the strongest 
association in Caucasian was only modestly associated with E2/T level (p=0.023) 


























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































。 丨 : I i I I I 
I 24 T I 24 � ** 
5 23 J _ 丄 o 22 C1 
I 22] . I I 201 . I 
CC CT TT GG GT TT 
- 3 7 r ^ I 14。 i I 
n H f T t t i t= 0 34 ** ** 
- 3 2 | I S 28| . . I 
CC CT TT GG GT TT 
6.0] — 1 6.O1 1 
, I 二 I 
二 5.0 1 CM ** 
^ J 丄 I : x I 
S 4.0I . ^ I S 3.5] I 
CC CT TT GG GT TT 
(24.8%) (49.8%) ¢5.4%) (45.7%) (44.3%) (10.0%) 
Genotypes Genotypes 
Fisure 2.3.2.1, Serum sex steroid levels of subjects (mean 土 95% confidence interval) with 
different genotypes in the two CYP19A1 SNPs. 
One-way ANOVA test was adopted to detect the differences between sex steroid levels and 
genotypes. 
E2 = estradiol; T = testosterone. *P<0.05 by one way ANOVA test compared with CC 
genotype, **P<0.001 compared with GG genotype. 
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2.3.2.2 Halotype analysis and haplotype association in the tertile groups 
The 2 SNPs belong to different haploblocks on the CYP19A1 gene. 
Among the four possible haplotypes composed of rs2470152 and rs2899470, only 3 
haplotypes were prevalent in the Chinese population. The C-G, T-G and T-T 
haplotype accounted for more than 97% of all haplotypes. Also, the haplotype 
frequencies from HapMap data of two SNPs between CHB and Caucasian with 
European ancestry (CEU) were listed for comparison (Table 2.3.2.2.1), When I 
compared the haplotype frequencies between CHB and CEU (Hapmap phase II 
release 21a), it was found that the CHB appeared to have similar frequencies of T-T 
and T-G haplotypes (both at 0.217) while T-T was predominant over T-G haplotype 
in the Caucasians (0.322 and 0.101，respectively). 
T-G haplotype appeared to be risk haplotype for high serum E2 levels 
while the T-T haplotype was associated with low E2 levels. After permuation 
analysis correcting for multiple testing, there was significant association between 
C-G, T-T haplotype with serum E2/T ratio (p=0.019 and p=lxl0"5, respectively). 
Again, no association was found between haplotypes and serum T levels examined. 
When examined both E2 and E2/T together, only T-T haplotype showed persistent 
association with low E2 and E2/T. 
61 
Table 2.3.2.2.1 Haplotype association of the CYP19A1 gene and tertile groups (high vs. low) 
of serum steroid levels 
High Low Overall CHB CEU P P value 
tertile tertile frequency (HapMap (HapMap value after 10000 
(N=934) (N=934) Data) Data) permutions 
E2 
C-G 0.470 0.452 0.461 0.539 0.440 NS NS 
T-T 0.252 0.349 0.300 0.217 0.322 6xl0"6 lxlO"5 
T-G 0.253 0.168 0.211 0.217 0.101 6xl0"6 lxlO"5 
C-T 0.024 0.031 0.028 0.028 0.061 NS NS 
T 
C-G 0.465 0.478 0.471 NS NS 
T-T 0.273 0.296 0.284 NS NS 
T-G 0.238 0.192 0.215 0.0163 NS 
C-T 0.024 0.035 0.029 NS NS 
E2/T 
C-G 0.493 0.429 0.461 6xl0"3 0.019 
T-T 0.252 0.353 0.303 2><l(r6 1><10_5 
T-G 0.230 0.187 0.208 0.0226 NS 
0.026 0.031 0.028 NS NS 
Haplotypes are composed with 2 SNPs (rs2470152 and rs2899470) in the CYP19A1 gene. 
Haploview 4.1 was used to infer haplotypes using an accelerated expectation maximization 
algorithm using the tertile group analysis. N equals to numbers of chromosomes in either high 
tertile and low tertile groups.The haplotype frequencies of two SNPs between CHB and CEU 
were listed for comparison. 
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2.3.2.3 Haplotype construction of 3 SNPs 
In order to examine the ability to tag coding SNPs by these two genotyped SNPs, I 
retrieve all coding SNPs in CYP19A1 gene from dbSNP, and found 7 coding SNPs (cSNPs) 
resulted in amino acid changes in CYP19A1 gene. Only two SNPs (rs700519 and rs2236722) 
were present at allelic frequencies of 5% or above. Haplotypes of these two SNPs, together 
with two SNPs in my study were examined. The haplotypes were constructed with by 
haploview (Table 2.3.2.3.1), Six haplotypes were observed with haplotype frequency>3%. 
For the haplotype constructed by rs2470152, rs2899470, and rs700519,1 observed that TGA 
haplotype was unique in CHB. In addition, the TGA and CGA haplotype which was thought 
to have bearing with high serum steroid levels showed higher frequency in CHB than CEU. 
On the other hand, the TTG haplotype which was thought to be associated with low serum 
steroid levels was less in CHB than CEU. As for rs2236722, the G (minor allele) always 
showed up with minor haplotype TT in CHB, while the CEU is absent from this allele. The 
TTG haplotype may be associated with low serum steroid levels in CHB. This analysis 
revealed a marked difference in haplotype frequencies of the chromosomes carrying cSNP 
across different populations. This may account for the differences in association SNPs in 
different ethnic groups. 
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Table 2.3.2.3.1 Haplotype information for tested haplotype with the coding SNPs in 
CYP19A1 gene region 
Tested Haplotype cSNP CHB CEU 
(rs2899470-rs2470152) rs700519 
OVG) 
CG CGA 0.090 0.029 
CGG 0.27 0.43 
TT TTA Absent Absent 
TIG 0.14 0.32 
TG IGA 0.084 Absent 
IGG 0.26 0.12 
CT CTA Absent Absent 
CTG 0.16 0.07 
Tested Haplotype cSNP CHB CEU 
(rs2899470-rs2470152) rs2236722 
(A^G) 
CG CGG Absent Absent 
CGA 0.55 0.44 
TT U G 0.03 Absent 
TTA 0.19 0.32 
TG IGG Absent Absent 
IGA 0.22 0.11 
CT CTG 0.01 Absent 
CTA 0.02 0.06 
Note: The additional haplotype data cSNP were retrieved form HapMap dataset. The cSNP 
were located 3' to the 2 SNPs genotyped here. 
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2.3.3 SRD5A1 
2.3.3.1 Association of SRD5A1 and sex steroid levels 
The genotype and allele frequencies for the 3 SNPs ( rs248807, rsll738248, rs824811) 
on SRD5A1 are shown in Table 2.3.3.1.1, Genotype frequencies of both SNPs did not deviate 
from HWE (p>0.05). 
The univariate association of these SNPs with serum steroid levels was shown in Table 
2.3.3.1.2. The DHT/T ratio was significantly different in rsl 1738248 while the DHT level was 
significantly different in rs824811 (p二0.036, p=0.021, respectively). For rsl 1738248, the 
DHT/T ratio was significantly higher in CC genotype compared with CT genotype (p=0.03). 
For rs824811, the DHT level was significantly higher in CC genotype compared with CT 
genotype (p=0.03, indicated in Fisure 2.3.3.1). The SNP rsl 1738248 in SRD5A1 was 
significantly associated with serum DHT/T ratio after the adjustment of confounding factors 
such as age, BMI, smoking and drinking status, and serum sex hormone binding globulin 
(SHBG) level (p=0.03, Table 2.3.3.1.3), However, the SNP rs824811, which showed 
association with DHT level in one-way ANOVA test, was no longer significantly associated 























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 2.3.3.1.3 Association of rsl 1738248 with DHT/T levels in linear regression 




Model B Std. Error Beta t Sig. 
"1 (Constant) ！056 ！OH 3.999 .000 
rsll738248(CT) -.003 .002 -.063 -2.179 .030 
Age .001 .000 .106 3.638 .000 
BMI -.001 .000 -.066 -2.035 .042 
riGARETTE 
SMOKING STATUS - 0 0 1 . 0 0 1 _ . 0 1 5 - 4 9 4 . 6 2 2 
Ever d r ink�12 
, , , . , . , -.001 .002 -.010 -.352 .725 alcoholic drinks 
sex hormone binding „„„ … , � „„„ 
globulin (nmol/liter) . 1 2 1 3 . 6 9 5 . _ 
a. Dependent Variable: DHT/T 
Linear regression analyzes of the predictive role of rsl 173 8248 for DHT/T ratio in 
Chinese men. P-values were calculated using liner regression under an additive 
model, such that genotypes for the SPSS from 1 to 3, according to the order of 
genotypes in Table 2.3.3.1.1, 
P values were corrected for age, BMI, smoking and drinking status, and serum sex 
hormone binding globulin (SHBG) level. 
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Table 2.3.3.1.4 Association of rs824811 with DHT level in linear regression models 




Model B Std. Error Beta t Sig. 
"1 (Constant) ！607 ！093 6.540 .000 
Age -.003 .001 -.073 -3.240 .001 
BMI -.008 .002 -.110 -4.411 .000 
CIGARETTE 
SMOKING STATUS _.003 _.010 "“440 . 6 6 0 
Ever drink�12 
, u r -.008 .011 -.016 -.707 .480 alcoholic drinks 
sex hormone binding ^^^ 
, u r , 1/r+ f .007 .000 .612 24.349 .000 globulin (nmol/hter) 
rs824811(CT) -£19 £ U -.037 -1.678 .094 
a. Dependent Variable: dihydrotestosterone (ng/ml) 
Linear regression analyzes of the predictive role of rs824811 for DHT level in 
Chinese men. P-values were calculated using liner regression under an additive 
model, such that genotypes for the SPSS from 1 to 3, according to the order of 
genotypes in Table 2.3.3.1.1. 
P values were corrected for age, BMI, smoking and drinking status, and serum sex 
hormone binding globulin (SHBG) level. 
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2.3.3.2 Haplotype analysis and haplotype association in the fertile groups 
Four possible haplotypes were composed by 3 SNPs on SRD5A1 gene. 
The C-C-T haplotype accounted for nearly 50% of chromosome in the population 
sample while A-C-T haplotype accounted for about 25% of all haplotypes. C-T-T and 
C-C-C accounted for about 15% and 10% population haplotypes, respectively (Table 
2.3.3.2.1). C-T-T haplotype appeared to be risk haplotype for low serum DHT levels 
or DHT/T ratio by nominal chi-square (p=0.012, p=0.039, respectively). After 
permutation analysis correcting for multiple testings, there was still a significant 
association between C-T-T haplotype with serum DHT level (p=0.045). However, no 
association was found between haplotypes and serum T levels examined. 
Table 2.3.3.2.1 Haplotype association of the SRD5A1 gene and tertile groups (high 
vs. low) of serum steroid levels 
rs248807&rsll738248 High Low Overall P P value 
&rs824811 tertile tertile frequency value after 10000 
(N=934) (N=934) permutions 
DHT 
C-C-T 0.494 0.506 0.500 0.627 0.999 
A-C-T 0.249 0.221 0.235 0.185 0.508 
C-T-T 0.132 0.179 0.156 0.012 0.045 
C-C-C 0.123 0.094 0.108 0.062 0.212 
T 
C-C-T 0.486 0.519 0.502 0.1873 -
A-C-T 0.254 0.228 0.241 0.2259 -
C-T-T 0.140 0.151 0.145 0.5475 -
C-C-C 0.120 0.101 0.111 0.2228 -
DHT/T 
C-C-T 0.510 0.527 0.519 0.520 0.977 
A-C-T 0.235 0.209 0.222 0.217 0.571 
C-T-T 0.138 0.176 0.158 0.039 0.141 
C-C-C 0.114 0.087 0.100 0.073 0.248 
Haplotypes are composed with three SNPs (rs248807&rsll738248&rs824811) in the 




2.3.4.1 Association of SRD5A2 and sex steroid levels 
The genotype and allele frequencies for the 3 SNPs (rs3731586, rsl2470143, 
rs523349 (V89L)) on SRD5A2 are shown in Table 2.3.4.1.1, Genotype frequencies 
of both SNPs did not deviate from HWE (p>0.05). 
The univariate association of these SNPs with serum steroid levels was shown 
in Table 2.3.4.1.2, The 3 a -diolG level was significantly different among genotypes 
of rsl2470143, (p=0.039, indicated in Fisure 2,3.4.1�. The SNP rsl2470143 in 
SRD5A2 was significantly associated with serum 3 a -diolG even after the 
adjustment of confounding factors such as age, BMI, smoking and drinking status, 
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! 1 1 
CC CT TT 
rsl2470143(CT) 
Fisure 2.3.4.1 Association between rsl2470143 and 3 a -diolG level. 
3 a -diolG= androstane-3 a, 17b-diol3glucuronide. 
Table 2.3.4.1.3 Association of rsl 2470143 on SRD5A2 with 3 a -diolG level in 




Model B Std. Error Beta t Sig. 
"I (Constant) ！853 ！415 2.057 .040 
rsl2470143(CT) -.084 .035 -.070 -2.430 .015 
Age .002 .005 .013 .457 .647 
BMI .017 .008 .066 2.035 .042 
CIGARETTE 
SMOKING STATUS . 0 1 3 ‘ 0 3 6 . 0 1 1 - 3 6 3 - 7 1 7 
Ever dr ink�12 
alcoholic drinks . 0 2 1 . 0 5 3 . 0 1 2 3 9 8 6 9 1 
sex hormone binding 
globulin (nmol/liter) _ . 0 0 7 . 0 0 1 - 1 8 0 ' 5 - 5 2 4 • _ 
a . Dependent Variable: androstane-3 a, 17b-diol 3glucuronide (ng/ml) 
Linear regression analyzes of the predictive role of rsl 2470143 for 3 a -diolG in 
Chinese men. P-values were calculated using liner regression under an additive 
model, according to the order of genotypes in Table 2.3.4.1.1, P values were 
corrected for age, BMI, smoking and drinking status, and serum SHBG level. 
75 
2.3.4.2 Haplotype association analysis of SRD5A2 in tertile groups 
Four possible haplotypes were composed by 3 SNPs on SRD5A2 gene. 
The A-C-G and A-T-C haplotype accounted for nearly 90% of all haplotypes. (Table 
2.3.4.2.1). No association was found between haplotypes and serum 3 a -diolG level 
examined. 
Table 2.3.4.2.1 Haplotype association of the SRD5A2 gene and tertile groups (high 
vs. low) of 3 a -diolG level. 
rs3731586&rsl2470143 3 a -diolG Overall frequency P value 
&rs523349(V89L) 
High tertile Low tertile 
(N=924) (N=970) 
A-C-G 0.574 0.541 0.557 0.19 
A-T-C 0.301 0.339 0.32 0.10 
G-C-C 0.096 0.088 0.092 0.62 
A-C-C 0 . 0 2 3 0.025 0 . 0 2 4 0,75 
Haplotypes are composed with 3 SNPs (rs3731586 & rsl2470143 & rs523349) in the 
SRD5A2 gene. Haploview 4.1 was used to infer haplotypes using an accelerated 
expectation maximization algorithm using the tertile group analysis. N equals to 
numbers of chromosomes in either high tertile and low tertile groups. 
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2.3.5 HSD3B1 
2.3.5.1 Association of HSD3B1 and sex steroid levels 
The genotype and allele frequencies for the 2 SNPs 
(rsl2022215&rs879332) on HSD3B1 are shown in Table 2.3.5.1.1. Genotype 
frequencies of both SNPs did not deviate from HWE (p>0.05). 
The univariate association of these SNPs with serum steroid levels was 
shown in Table 2.3.5.1.2, However, No association between sex steroid levels and 2 

































































































































































































































































































































































































































































































































































































































































































































































































































































































2.3.6.1 Association of HSD17B2 and sex steroid levels 
The genotype and allele frequencies for the 4 SNPs (rsl364286, rs2966241, 
rs2955162, rsl364283) on HSD17B2 are listed in Table 2J.6.U. Genotype 
frequencies of all SNPs did not deviate from HWE (p>0.05). 
The univariate association of these SNPs with serum steroid levels afer the 
adjustement of age and BMI was shown in Table 2.3.6.1.2, The DHT/T ratio was 
significantly different among genotype of rsl 364286 (p=0.007). Furthermore, the 
SNP rsl364283 was associated with El , adione, T and DHT levels significantly 
(p=0.031，p=0.035, p=0.027, p=0.026, respectively). Fieure 2.3.6.1 shows the 
association between SNPs of HSD17B2 and sex steroid levels with P values in post 
hoc test. As for rsl364286, the DHT/T ratio was significantly higher in GG genotype 
compared with AG genotype (p=0.003). As for rsl 364283, the adrostenedione level 
was significantly higher in CC genotype compared with AA genotype (p=0.031). 
However, the El, DHT and T levels in rsl364283 were not significantly different 
compared with each genotype although the overall p values were significant (data not 
shown). In addition, the SNP rsl364286 was not associated with serum DHT/T ratio 
after adjustment of other demographic and environmental factors in linear regression 
model (p=0.502, indicated in Table 2.3.6.1.3), As for the SNP rsl364283, it remained 
80 
to be significantly associated with El, T, DHT and Adione levels after adjustment for 
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0.0825-1 
�Ki Ai AA 
rsl 364286( Ad) 
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0.775H 
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0.675H 
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CC AC AA 
rsl364283(AC) 
Figure 2.3.6.1 Association between HSD17B2 and sex steroid levels. 
DHT=dihydrotestosterone, T=testosterone, adione=androstenedione. *P=0.003 






















































































































































































































































































































































































































































































































































































































































































































































































































































































2.3.6.2 Halotype association analysis of HSD17B2 in the fertile groups 
Among the 16 possible haplotypes composed of rs2966241, rsl364286， 
rs2955162 and rsl364283, only 3 haplotypes were prevalent in the population. The 
two prevalent haplotypes (A-A-G-A, A-G-G-C) were dominant in low T tertile group 
(about 60%). (Table 2,3,6.2.1). 
A-A-G-A haplotype was associated with for low serum T level while the 
A-A-G-C haplotype appeared to be a risk haplotype for high T level (p=0.031, 
p=0.034, respectively). After permuation analysis correcting for multiple testings, 
however, no more association was found between haplotypes and serum T level 
(indicated in Table 2.3.6.2.1), 
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Table 2,3.6.2.1 Haplotype association of the HSD17B2 gene and tertile groups (high 
vs. low) of serum steroid levels 
HSD17B2 High Low Overall P P value 
tertile tertile frequency value after 10000 
(N=930) (N=936) permutions 
T 
A-A-G-A 0.320 0.372 0.346 0.031 NS 
A-G-G-C 0.219 0.233 0.226 NS NS 
A-A-G-C 0.244 0.200 0.222 0.034 NS 
G-G-G-C 0.094 0.080 0.087 NS NS 
A-G-A-A 0.047 0.049 0.048 NS NS 
A-G-A-C 0.047 0.034 0.041 NS NS 
A-G-G-A 0.013 0.023 0.018 NS NS 
G-G-G-A 0.015 0.009 0012 NS NS 
Haplotypes are composed with 4 SNPs (rs2966241, rsl364286, rs2955162, 
rsl364283) in the HSD17B2 gene. Haploview 4.1 was used to infer haplotypes using 
an accelerated expectation maximization algorithm using the tertile group analysis. 
N equals to numbers of chromosomes in either high tertile and low tertile groups. 
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2.3.7 AKR1C4 
2.3.7.1 Association of AKR1C4 and sex steroid levels 
The genotype and allele frequencies for the 2 SNPs (rsl334473 and 
rsl7134607) on AKR1C4 are listed in Table 2.3.7.1.1, Genotype frequencies of all 
SNPs did not deviate from HWE (p>0.05). 
The univariate association of these SNPs with serum steroid levels afer the 
adjustement of age and BMI was shown in Table 2.3.7.1.2. The androsterone level 
was significantly different in rsl7134607 (p=0.003). Fisure 2,3.7.1 shows the 
association between rsl7134607 and androsterone levels with P values in post hoc 
test. The adrosterone level was significantly lower in GG genotype compared with 
AA genotype (p=0.013). In addition, the SNP rsl7134607 was significantly 
associated with adrosterone level after adjustment for demographic, life style factors 
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1 (78 2%) (204%) (1.4%) 
GG AG AA 
rsl7134607(AG) 
Fisure 2.3.7.1 Association between rsl7134607 and androsterone levels. Adt 
=androsterone. *P=0.013 compared with AA 
Table 2.3.7.1.3 Association of rsl7134607 on AKR1C4 with Adt level in linear 




Model B Std. Error Beta t Sig. 
~ (Constant) ！453 ！042 10.790 .000 
rsl7134607(AG) .016 .005 .090 3.179 .002 
Age -.002 .000 -.111 -3.849 .000 
BMI -.005 .001 -.203 -6.357 .000 
CIGARETTE 
SMOKING STATUS ‘ 0 0 3 ‘ 0 0 4 ‘ 0 2 7 ‘ 9 3 7 ‘ 3 4 9 
Ever d r ink�12 
alcoholic drinks - 0 0 3 . 0 0 5 - 0 1 9 - 6 3 8 . 5 2 3 
sex hormone binding 
globulin (nmol/liter) 5 . 6 2 E _ 0 0 5 . 0 0 0 . 0 1 4 . 4 1 9 . 6 7 5 
a- Dependent Variable: androsterone (ng/ml) 
Linear regression analyzes of the predictive role of rsl 7134607 for Adt level in 
Chinese men. P-values were calculated using liner regression under an additive 
model, such that genotypes for the SPSS from 1 to 3, according to the order of 
genotypes in Table 2.3.7.1,1. P values were corrected for life style factors. 
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2.3.7.2 Halotype association analysis ofAKRlC4 in the tertile groups 
Among the three possible haplotypes composed of rsl334473 and 
rsl7134607，G-G haplotype was prevalent (>60%) while the G-A haplotype 
accounted for about 11% in the population. (Table 2.3.7.2.1�. 
G-A haplotype was associated with high serum adrosterone level (p=0.019), 
but it was only marginally significant after permutation analysis correcting for 
multiple testing. (p=0.05) (indicated in Table 2.3.7.2.1). 
Table 2.3.7.2.1 Haplotype association of the AKR1C4 and tertile groups (high vs. 
low) of serum steroid levels 
AKR1C4 High Low Overall P P value 
(rsl334473& tertile tertile frequency value after 10000 
rsl7134607) (N=772) (N=784) permutions 
Adt 
G-G 0.614 0.637 0.626 NS NS 
A-G 0.254 0.268 0.261 NS NS 
G-A 0.132 0.094 0.113 0.019 0.049 
Haplotypes are composed with 2 SNPs (rsl334473 and rsl7134607) in the AKR1C4 
gene. Haploview 4.1 was used to infer haplotypes using an accelerated expectation 
maximization algorithm using the tertile group analysis. N equals to numbers of 
chromosomes in either high tertile and low tertile groups. 
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2.3.8 AKR1D1 
2.3.8.1 Association ofAKRIDI and sex steroid levels 
The genotype and allele frequencies for the 2 SNPs (rsl 1982192 and 
rs2306845) on AKR1D1 are listed in Table 2.3.8.1.1, Genotype frequencies of all 
SNPs did not deviate from HWE (p>0.05). 
The univariate association of these SNPs with serum steroid levels after the 
adjustement of age and BMI was shown in Table 2.3.8.1.2, The DHT level was 
significantly different for genotypes of both rsll982192 and rs2306845 (p=0.019, 
p=0.002, respectively). In addition, T level was significantly different in rs2306845 
(p=0.014) Fisure 2.3.8.1 shows the association between two SNPs on AKR1D1 and 
sex steroid levels with P values in post hoc test. As for the SNP rs2306845, the T and 
DHT levels were significantly lower in GG genotype compared with TT genotype 
(p=0.027, p=0.005, respectively). However, the DHT level in SNP rsll982192 was 
not different compared with each genotype group although it had an overall 
significant p value 0.019 (indicated in Fisure 2.3.8.1) In the linear regression model, 
rsl 1982192 was significantly associated with DHT level after adjustment for 






































































































































































































































































































































































Table 2.3.8.1.2 Univariate association between genotype and age and BMI adjusted 
total steroid levels 
Genotype T(ng/ml) DHT DHT/T SHBG(nmol/l) 
(ng/ml) 
rsll982192 GG 5.41±2.19 0.43±0.21 0.080士0.025 49.81 士 18.71 
(5.8%) 
(N=1120) GT 5.36±1.95 0.46士0.22 0.087士0.028 48.93士 18.56 
(37.9%) 
TT 5.57 士2.05 0.48士0.22 0.088士0.027 50.72±20.99 
(56.2%) 
P value 0.27 0.019 0.06 0.36 
rs2306845 GG 5.49士2.00 0.47±0.22 0.087士0.026 49.89士 18.78 
(67.1%) 
(N=1131) GT 5.32±1.85 0.45士0.21 0.086士0.027 48.79士 20.70 
(28.4%) 
TT 6.24士2.53 0.57士0.30 0.090±0.021 53.83士25.51 
(4.5%) 
P value 0.014 0.002 0.600 009 
T=testosterone, DHT=dihydrotestosterone, SHBG=sex hormone binding globulin, 
Values are given as mean士SD. P values are for comparison of the three genotypes 










































































































































































































Table 2.3.8.1.3 Association of two SNPs on AKR1D1 with sex steroid levels in linear 
regression models including demographic, life style factors and SHBG. 
T DHT DHT/T 
P 士 S.E P |3 士 S.E P (3 士 S.E P 
value value value 
rsll982192 - - 0.019士0.008 0 . 0 2 3 0.002士0.001 0.059 
Age - - -0.003士0.001 0.002 0.001士0.000 <0.001 
BMI - - -0.008士0.002 <0.001 -0.001士0.000 0.031 
Smokers - - -0.006±0.008 0.465 -0.001 士0.001 0.423 
Drinkers - - -0.008士0.012 0.509 -0.001 士0.002 0.631 
SHBG - - 0.007士 0.001 <0.001 0.000士0.000 0.001 
rs2306845 0.002士0.071 0.982 0.006士0.009 0.482 - -
Age -0.068士0.008 <0.001 -0.003士0.001 0.001 - -
BMI -0.052士 0.015 <0.001 -0.008士0.002 0.000 - -
Smokers -0.037士0.063 0.563 -0.004士0.008 0.584 - -
Drinkers 0.066±0.092 0.473 -0.006士0.011 0.583 - -
SHBG 0.072士0.002 <0.001 0.007士0.000 <0.001 - -
Linear regression analyzes of the predictive role of rsl 1982192 and rs2306845 for 
serum sex steroid levels in Chinese men. 
P-values were calculated using liner regression under an additive model, such that 
genotypes for the SPSS from 1 to 3, according to the order of genotypes in table 
2.3.8.1.1. T=testosterone, DHT=dihydrotestosterone. P values were corrected for age, 
BMI, smoking and drinking status, and serum sex hormone binding globulin (SHBG) 
level. 
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2.3.8.2 Haplotype association analysis of AKR1D1 in the tertile groups 
Among the three possible haplotypes composed of rs2301845 and 
rsl 1982192, G-T haplotype was prevalent (about 60%) in the population (Table 
2.3.8.2.1X 
T-T haplotype appeared to be a risk haplotype for high serum DHT level 
(p=0.030). However, it was not associated with DHT level after permutation analysis 
correcting for multiple testing (indicated in Table 2.3.8.2.1). 
Table 2.3.8.2.1 Haplotype association of the AKR1D1 and tertile groups (high vs. 
low) of serum steroid levels 
AKR1D1 High Low Overall P P value 
(rs2306845& tertile tertile frequency value after 10000 
rsll982192) (N=796) (N=796) permutions 
T 
G-T 0.595 0.559 0.577 NS -
G-G 0.220 0.258 0.239 NS -
T-T 0.182 0.178 0.180 NS -
DHT High Low 
tertile tertile 
(N=796) (N=800) 
G-T 0.590 0.554 0.572 NS NS 
G-G 0.232 0.279 0.256 NS NS 
T-T 0.175 0.162 0.168 0.030 NS 
DHT/T High Low 
tertile tertile 
(N=766) (N=806) 
G-T 0.585 0.553 0.568 NS NS 
G-G 0.225 0.271 0.249 0.039 NS 
T-T 0.185 0.174 0.179 NS NS 
Haplotypes are composed with two SNPs (rs2306845 and rsll982192) in the 
AKR1D1 gene. Haploview 4.1 was used to infer haplotypes using an accelerated 
expectation maximization algorithm using the tertile group analysis. N equals to 
numbers of chromosomes in either high tertile and low tertile groups. 
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2.3.9 AKR1C3 
2.3.9.1 Association of AKR1C3 and sex steroid levels 
The genotype and allele frequencies for the 2 SNPs (rs4881400 and 
rsl 1252940) on AKR1C3 are listed in Table 2.3.9.1.1, Genotype frequencies of all 
SNPs did not deviate from HWE (p>0.05). 
The univariate association of these SNPs with serum steroid levels after the 
adjustement of age and BMI was shown in Table 2.3.9.1.2. The DHT/T ratio was 
significantly different in rs4881400 (p=0.02). Fisure 2.3.9.1 shows the association 
between rs4881400 and DHT/T ratio with P values in post hoc test. The DHT/T ratio 
were significantly lower in GG genotype compared with GT genotype (p=0.017). 
However, in the linear regression model, rs48801400 was not significantly associated 
with DHT/T ratio after adjustment for demographic, life style factors and SHBG 
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rs4881400(GT) 
Fisure 2.3.9.1 Association between rs4881400 and DHT/T ratio. 
DHT=dihydrotestosterone, T=testosterone.*P=0.017 compared with GG 
Table 23,9.1.3 Association of rs4881400 on AKR1C3 with sex steroid levels in 
linear regression models including demographic, life style factors and SHBG. 
T D m DHT/T 
P 士 S.E P (3±S.E P p±S.E P 
value value value 
rs4881400 -0.040士0.060 0.505 0.007士0.007 0.319 0.002±0.001 0.150 
Age -0.071 士0.008 <0.001 -0.003士0.001 0.001 0.001 士0.000 <0.001 
BMI -0.059±0.015 <0.001 -0.008士0.002 <0.001 -O.OOliO.OOO 0.031 
Smokers -0.030士0.064 0.638 -0.006士0.008 0.504 -O.OOliO.OOl 0.423 
Drinkers 0.044士0.092 0.632 -0.008±0.011 0.598 -0.001士0.002 0.631 
SHBG 0.071 士0.002 <0.001 0.007士 0.001 <0.001 0.000士0.000 0.001 
Linear regression analyzes of the predictive role of rs4881400 for serum sex steroid 
levels in Chinese men. 
P-values were calculated using liner regression under an additive model, such that 
genotypes for the SPSS from 1 to 3，according to the order of genotypes in table 
2.3.9.1.1. T=testosterone, DHT=dihydrotestosterone. P values were corrected for age, 
BMI, smoking and drinking status, and serum sex hormone binding globulin (SHBG) 
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2.3.9.2 Haplotype association analysis of AKR1C3 in the tertile groups 
Among the four possible haplotypes composed by rs4881400 and 
rsl 1252940, G-A and T-T haplotype was prevalent (about 85%) in the population 
(Table 2.3.9,2.1). 
G-A haplotype had borderlined significant value in association with 
DHT/T ratio (p=0.067). However, it was not associated with DHT/T ratio after 
permutation analysis correcting for multiple testing (indicated in Table 2.3,9.2.1). 
Table 2.3.9.2.1 Haplotype association of the AKR1C3 and tertile groups (high vs. 
low) of serum steroid levels 
AKR1C3 High Low Overall P P value 
(rs4881400& tertile tertile frequency value after 10000 
rsll252940) (N=766) (N=806) permutions 
DHT/T 
G-A 0.597 0.642 0.620 0.067 NS 
T-T 0.225 0.207 0.216 0.401 NS 
T-A 0.156 0.129 0.142 0.126 NS 
G-T 0.023 0.022 0.022 0.958 NS 
Haplotypes are composed with 2 SNPs (rs4881400 and rsll252940) in the AKR1C3 
gene. Haploview 4.1 was used to infer haplotypes using an accelerated expectation 
maximization algorithm using the tertile group analysis. 
N equals to numbers of chromosomes in either high tertile and low tertile groups. 
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2.3.10 Overall association of polymorphisms in sex steroid 
metabolism genes and metabolites levels in blood 
Table 2J.10.1 showed that only CYP19A1, SRD5A1 and AKRl C4 
polymorphisms were significantly associated with certain sex steroid levels after all 
statistical tests. 
Table 2,3.10.1 Overall association of polymorphisms in sex steroid metabolism 




Gene strongly Univariate Linear 
between tertile groups 
associated analysis regression 
(permutation) 
Replication study of CYP19A1 
CYP19A1 E2 or E2/T <0.001 <0.001 IxlQ'^ 
New association study of androgen metabolites 
SRD5A1 DHT/T or DHT 0.036 0.030 0.045 
SRD5A2 3 a -diolG 0.039 0.015 NS 
HSD3B1 - NS NS NS 
HSD17B2 DHT/T 0.007 NS NS 
T 0.027 0.023 NS 
AKR1C4 Adt 0.003 0.002 0.049 
AKRIDI DHT 0.002 0.023 NS 
AKR1C3 DHT/T ^ ^ ^ 
T=testosterone, DHT=dihydrotestosterone, 3 a -diolG= androstane-3 
a , 17b-diol3glucuronide, Adt=androsterone. 
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2.4 Discussion 
2.4.1 SRD5A and sex steroid levels 
This study in Chinese men suggested that rsl 1738248 in SRD5A1 was 
significantly associated with circulating DHT/T ratio (p=0.03) while the C-T-T 
haplotype on SRD5A1 could be a predictor for low DHT level (p=0.045 after 10000 
permutation test). Although the genotype of rsl2470143 in SRD5A2 was 
significantly associated with serum 3 a -diolG level (p=0.015), and TT genotype 
predicts lower 3 a -diolG level, the association did not persist in the haplotype 
analysis of tertile groups. 
The SRD5A1 gene is located on chromosome 5 at 5pl5.5 (Jenkins, Hsieh 
et al. 1991)，while SRD5A2 is located on chromosome 2 at 2p23 (Chu, Reichardt et 
al. 2008). These two genes encoding enzymes play an important role in converting T 
to its more potent biological form, DHT, and then DHT could be reduced to its 
metabolites 3 a -diolG. Therefore, the DHT, DHT/T and 3 a -diolG. could all be 
potential indicators of 5 a -reductase activity (Hayes, Severi et al. 2007). In addition, 
DHT is mostly derived from SRD5A1/SRD5A2 activity and DHT or DHT/T could 
be a marker for SRD5A1 or SRD5A2 activity, while 3 a -diolG metabolites are 
believed to be a more accurate marker of SRD5A2 activity alone(Hayes, Severi et al. 
2007). 
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Previous findings suggested SRD5A1 polymorphisms were associated with 
DHT/T ratio. The homozygous A alleles on SRD5A1 Hinfl SNP was indicated to be 
significantly associated with higher serum DHT/T ratio (P=0.009) (Ellis, 
Panagiotopoulos et al. 2005). In this study, this functional SNP was not included, but 
instead, three intronic SNPs on the same gene were included and rsl 1738248 was 
observed to be significantly associated with serum DHT level while the C-T-T 
haplotype could be a risk haplotype for low DHT level. This finding provided further 
support to the previous study by Ellis et.al that the SRD5A1 polymorphisms could 
predict DHT level or DHT/T ratio, which was associated with intra-cellular 5 a 
-reductase activity. Although the SNP markers used in the study have no known 
influence on the amino acid alterations of the enzyme, it is possible that other 
functional alleles exit in or around this gene that are in LD (linkage disequilibrium) 
with these tagSNPs. 
It has been indicated that SRD5A2 polymorphisms mediate their effects 
through alterations in androgen levels, including T, DHT, or 3 a -diolQ a major 
metabolite of DHT (Hayes, Severi et al. 2007). Previous studies found conflicting 
results about SRD5A2 polymorphisms and T levels among different groups (Allen, 
Forrest et al. 2001; Allen, Reichardt et al. 2003; Hayes, Severi et al. 2007).No 
association was found between V89L and serum T level in Asian men (Makridakis, 
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Ross et al. 1997), but contradictory results have been observed in two studies among 
European population(Allen, Forrest et al. 2001; Hayes, Severi et al. 2007). In 
addition, both studies carried out by Allen et.al and Hayes et.al in European men 
have confirmed an association between A49T in SRD5A2 and serum 3 a -diolG level 
(Allen, Forrest et al. 2001; Hayes, Severi et al. 2007). The present studies in Chinese 
men found that no associations between V89L in SRD5A2 and serum T level, which 
was also in keep with the other study of Asian population (Makridakis, Ross et al. 
1997). In addition, it was also found that another SNP, rsl2470143, which locates in 
the intron 1 of SRD5A2, could be a predictor for circulating 3 a -diolG levels. 
Whether this SNP exert effect on amino acid change alone or in LD with other 
functional alleles is still not known. However, all the results together indicated that 
SRD5A2 polymorphisms might be a predictor on circulating 3 a -diolG levels in 
Asian men. However, such association with SRD5A2 fell short of significance in 
further haplotype analysis. 
In conclusion, previous studies were confirmed that SRD5A1 gene 
polymorphisms are associated with DHT or DHT/T ratio while SRD5A2 gene 
variants might have small effect on serum 3 a -diolG levels. However, the findings 
also raise a number of questions; including whether SNPs observed in this study 
exert their influence on androgen levels alone or together with other allele, or how 
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they affect the activities of the two 5 a -reductase. Future studies are required to 
elucidate the relationship between SRD5A and serum androgen levels, and to explore 
the underlying functional SNPs of these two genes. 
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2.4.2 HSD17B2 and sex steroid levels 
This study showed association between HSD17B2 polymorphisms and sex 
steroid levels in serum. The SNP rsl364283 associated with El, T, DHT and 
androstenedion levels in linear regression model. However, this association was no 
longer persist in the haplotype analysis of tertile groups. 
HSD17B2 encoding enzyme, which distributed among many 
extraglandular tissues and liver, catalyzes the conversion of the inactive C19-steroid 
androstenedione to the biologically active androgen, testosterone (Moghrabi, Hughes 
et al. 1998). In addition, it is also responsible for the oxidation (inactivation) of E2 to 
El (Olson, Bandera et al. 2007). Previous findings have suggested that HSD17B1, 
the isoform of HSD17B2, which is responsible for the reduction of El to E2, was 
associated with circulating estradiol levels in women (Setiawan et al. 2004). 
However, there is a lack of evidence whether HSD17B2 polymorphisms are in 
association with sex steroid levels in men. 
In this study, it was found that the SNP1364283, which located in the 
intron 4 ofHSD17B2, associated with serum El, T，adione, and DHT levels. Since 
HSD17B2 encoding enzyme, the 17/3 -hydrosteroid dehydrogenase 2 plays a key 
role in converting androstenedione to its more potent biological form, T, and also 
take part in the reduction of E2 to El (Olson, Bandera et al. 2007), it is plausible that 
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the 17 yS -hydrosteroid dehydrogenase 2 activity could influence T, adrostenedione 
and El levels at the same t i m e 广 2 , 4 , 2 J ) . \ n addition, T could then be converted 
to its more potent form DHT in the circulation system to play its biological function. 
Therefore, the serum DHT levels could also be associated with 17 /3 -hydrosteroid 
dehydrogenase 2 activity. This study may serve as the preliminary study indicating 
the relationship between HSD17B2 polymorphisms and sex steroid levels. 
Functional analysis about this gene and sex steroid levels is required to unravel how 
the SNP exerts its influence on sex steroid levels. 
Androstenedione HSD17B2 Icdt^qiI 




Estrone (El) HSD17B2 Estradiol (E2) • 
Fisure 2.4.2.1 Sex steroid metabolic pathway and HSD17B2 encoding enzyme 
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2.4.3 AKRIDI, AKR1C4, AKR1C3 and catabolic intermediates of 
sex steroids 
AKRIDI encodes for 5 曰-reductase which catalyze T to an inactive 
metabolites 5 /3 -DHT which may represent a catabolic pathway ofT(Palenno, 
Marazzi et al. 2008). 
AKR1C4 encodes for enzyme 3 a -hydroxysteroid dehydrogenase that 
breakdown the most potent natural androgen (DHT) into 3 a -diolG, a metabolite 
with minimal androgen activity (Dufort, Labrie et al. 2001). In addition, due to its 17 
-HSD activity, it could also convert the 3 a -diolG to androsterone(Penning et al. 
2004), and these two processes are interconvertible (Penning et al. 2000). 
AKR1C3 encoding enzyme, the isoform of type 1 3 a -hydroxysteroid 
dehydrogenas (AKR1C4), could highly efficiently catalyze androstenedione to T, and 
less efficiently inactivates DHT to its metabolite, 3 a -diolG.(Roberts, Bergstralh et al. 
2006). 
There were lack of studies regarding the relationship between AKRIDI, 
AKR1C4 polymorphisms and sex steroid levels. As for AKRl C3, one study in 2006 
reported an association with progesterone and estrogen levels, and another study 
conducted in 2007 observed that Glu77Gly polymorphisms in AKRl C3 predicted for 
lower T levels (Jakobsson, Palonek et al. 2007; Rizner, Smuc et al. 2006). 
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It was observed that rsl7134607 on AKR1C4 was associated with 
androsterone level in linear regression model. In addition, G-A haplotype which was 
composed by two SNPs on AKR1C4 could be a risk haplotype for high androsterone 
level. Since the AKR1C4 encoding enzyme metabolizes DHT to 3 a -diolG, and then 
3 a -diolG could be reduced to androsterone under the regulation of the same enzyme, 
it is plausible that the AKR1C4 polymorphisms could be associated with 3 a 
-hydroxysteroid dehydrogenase activity which may have an influence on 
androsterone levels. 
In this study, it was observed that rsl 1982192，which located in intron 7 on 
AKRIDI was significantly associated with DHT level in linear regression model. It 
represents a preliminary investigation of the AKRlDl polymorphisms and its 
relationship with androgen levels. Although the SNP marker used in this study has no 
known implication for amino acid alteration, the result suggests that this SNP may be 
in LD with other functional SNPs that could influence DHT level, which might be an 
indicative for 5 ^ -reductase activity. 
However, it was not confirmed the association between AKR1C3 
polymorphisms and sex steroid levels. Although the SNP rs4881400 appeared to be 
associated with DHT/T ratio in one way ANOVA test, the association was not persist 
in linear regression model. Due to its important role in sex steroid metabolic pathway 
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and previous reports, a larger sample size may be needed to detect the association 
between sex steroid levels and AKR1C3. 
2.4.4 HSD3B1 and sex steroid levels 
HSD3B1 gene, which located on chromosome lpl3.1, encodes for 
3 3 -hydroxysteroid dehydrogenase. This enzyme could regulate androstenedione 
and T production. 
There were lack of reports about relationship between HSD3B1 
polymorphisms and sex steroid level. In this study, no association between two SNPs 
(rsl2022215 and rs879332) on HSD3B1 polymorphisms and sex steroid levels was 
found, 
2.4.4 CYP19A1 and sex steroid levels 
In this replication study, the association between polymorphisms in the 
CYP19A1 and estrogen levels in serum was confirmed. Eriksson et al. have 
previously demonstrated that rs2470152 is a strong while rs2899470 is a modest 
predictor of serum E2 and El levels in Caucasian men (Eriksson, Lorentzon et al. 
2008), while in the present study of Chinese men, it was found that E2 and El levels 
were mainly, predicted by SNP rs2899470 (p<0.001) rather than rs2470152 (Eriksson, 
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Lorentzon et al. 2008). Both SNPs (rs2470152 and rs2899470) were found to be 
strongly associated with serum E2/T ratios (p=0.023, pO.OOl，respectively). In 
addition, when haplotypes were inferred with these two SNPs, it was observed that 
they belonged to different haploblock, which had similar modest LD both in HapMap 
CHB sample and in my samples (r^=0.39 and r^=0.32), and the haplotypes are more 
informative than SNP data. The haplotype C-G and T-G were associated with high 
E2 or E2/T ratios, and the T-T haplotype was persistently associated low E2 and E2/T 
ratio. 
The CYP19A1 gene localized at chromosome 15q21.2 encodes aromatase that 
is the key enzyme for estrogen biosynthesis (Bulun et al. 2004). The gene is 
composed of a 30kb coding region and a 93kb regulatory region, the latter containing 
at least 10 distinct tissue-specific promoters (Bulun et al. 2003). The SNP rs2899470, 
which located in the intron 10 of the CYP19A1 gene, was significantly associated 
with serum steroid levels including T, E2, and E2/T. As the gene is composed of 2 
haploblocks, it was presumed that haplotype, rather than SNP, would be more 
informative for the variations in the gene and may be a better determinant of serum 
sex steroid levels. Therefore, Haplotypes of these two SNPs were computed and it 
was found that T-T haplotype was consistently associated with low E2, either in 
terms of E2 level or E2/T ratio. 
115 
The difference in findings of the strongest association SNP in this study and 
Eriksson et al. may be the result of several interacting factors. The first and most 
significant is ethnical composition. Subjects in the study of Eriksson et al. (Eriksson, 
Lorentzon et al. 2008) were of Caucasian origin. Here, subjects in this study were 
Chinese men and it was observed (from table 2.3.2.2.1) that the haplotype 
frequencies of two SNPs were different between the two ethnic groups which may 
lead to discrepancy in the two studies. There was a marked difference in haplotype 
frequencies of T-T and T-G haplotypes and they had an opposite effect on E2 level. 
This result showed that T-G haplotype associated with high E2 and it was present in 
low frequency in CEU (0.10) than CHB (0.22). While T-T and T-G haplotype have 
opposite effect on E2 level, the different ethnical haplotype differences may account 
for the association between the first SNP (rs2470152) and E2 levels in the Caucasian. 
It is because over third-quarter (0.322/0.322+0.101) of the "T" allele ofrs2470152 
are on the T-T (low E2) haplotypes in the Caucasian, whereas, the "T" allele is 
equally distributed to the T-T (low E2) and T-G (high E2) haplotype in Chinese, an 
association between the first SNP (T) with low E2 levels in Caucasian may be due to 
the low frequencies of T-G haplotype. 
Secondly, other unknown SNPs in CYP19A1 may play important role in 
biosynthesis of estrogen, it could influence both testosterone and estrogen levels in 
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serum. The variance in sex steroid level is affected by differential enzyme kinetics of 
the aromatase; due to coding SNPs variations, the known coding and 
nonsynomymous SNPs of CYP19A1 were also retrieved. The nonsynonymous SNP 
rs700519 (Arg264Cys), which results in amino acid changes from Arg to Cys at 
codon 264, may also lead to a difference in aromatase activity and exert an effect on 
sex steroid levels (Long et al. 2006). It was observed that this allele was only 
confined (in strong LD) to the two "high E2" (ie. C-G and T-G) (Table 2,3,2,3,1). If 
this cSNP was indeed responsible for the association, the particularly high frequency 
of C-G-264Cys haplotype in CHB compared to CEU, may account for the reason for 
discrepancy between ethinic groups. The other coding SNP rs2236722, at codon 39， 
leads to amino acid changes from Tip to Arg (Hamaguchi et al. 2008). It was very 
rare in CEU. In CHB, the minor allele G ofrs2234722 was in LD with the "low E2" 
haplotype T-T. The allelic frequencies and haplotype variations in these cSNPs 
between two ethnic groups may also explain the differences between two studies 
(Table 2J,2JAl 
Thirdly, different life styles between Caucasian and Chinese may also 
contribute to difference between results found by Eriksson et al. and that in my study. 
The Caucasian men are more likely to have higher BMI compared with our Chinese 
men (Deurenberg et al. 2002), which could have an influence on sex steroid level. 
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In conclusion, this large study in a homogeneous sample of Chinese elderly 
population revealed haplotype of rs2899470 and rs2470152, rather than rs2899470 
alone, could be better predictor for the E2 level and E2/T ratio in serum. The 
discrepancy between my study and the study carried by Eriksson et al. may be 
accounted by the differences in haplotype frequencies in the two ethnic groups. 
Although the two SNPs examined in this study do not change the amino acid 
sequence of the enzyme, the results suggest that one or more functional variants are 
present in this gene that are in linkage equilibrium with these two SNPs. However, It 
could not be explained how these cSNPs influence serum steroid levels. Future 
studies with a multi-ethnic population are required to demonstrate the relationship 
between CYP19A1 and serum sex steroid levels, and elucidate the functional SNP of 
this gene. 
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Chapter 3 Part B study： Genetic variations in sex steroid 
metabolic pathway and association with HCC 
3.1 Introduction 
3.1.1 Previous genetic association studies of HCC on sex steroid 
metabolic pathways 
There are conflicting results in the association between SRD5A2 
polymorphisms and risk of HCC among different ethnics with various life styles. Yu 
et al. reported in 2001 that SRD5A2 V89L polymorphisms were statistically 
significantly associated with risk of HBV-related HCC in Taiwan (OR (VV versus 
LL genotype) = 2.47; 95% CI = 1.21 to 5.03; P =0.011) (Yu et al. 2001). Another 
study published in 2003, which examined five additional SNPs on SRD5A2 gene, 
confirmed the functional and primary role of V89L on SRD5A2 in predisposition to 
risk of HCC (OR=1.86，95%CI=1.02-3.39) (Sung et al. 2003). On the other hand, a 
study published in the same year, found that no association between SRD5A2 V89L 
polymorphisms and risk of HCV-related HCC in Italian population (Rossi et al. 
2003). However, it is apparent that the underlying pathogenesis of HCC and allelic 
frequencies are different between ethnic groups which may be the reason for the 
ethnic specific associations. 
Castagnetta et.al investigated aromatase (CYP19A1) enzyme activity and 
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expression in nontumoral, cirrhotic, and malignant human liver cells and pointed out 
that locally elevated estrogens and increased aromatase activity might contribute to 
the development of HCC. This result suggested that anti-aromatase agents might be a 
useful way for the treatment of HCC (Castagnetta et al. 2003). Other studies also 
reported that high level of aromatase was expressed in hepatocellular carcinoma 
(fibrolamellar type) (Agarwal et al. 1998). In addition, Yabuuchi et.al observed that 
higher aromatase activity was present in human HCC and was related to the degree 
of histologic differentiation (Yabuuchi et al. 1993). These data suggested that there 
was dysregulation/alteration of aromatase expression in HCC and suggested a role 
for this enzyme in the carcinogenesis pathway. 
3.1.2 Previous genetic association studies of HCC in other pathways 
Positive associations have been found between HCC and genes encoding 
for phase I and phase II detoxification enzymes (Huang, Chem et al. 2003; Sun, 
Wang et al. 2001). The gluthathione S- transferase T1 was found to be significantly 
associated with risk of HCC patients after controlling aflatoxin exposure effect (Sun, 
Wang et al. 2001). In addition, polymorphisms of the N-acetyltransferase gene 
conferred different susceptibilities according to the amount of red meat intake on 
HCC (Huang, Chem et al. 2003). 
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The association between other candidate genes involved in cell cycle 
regulation and DNA repair and risk of HCC have also been reported (Yu, Yang et al. 
2003; Zhang, Chen et al. 2002 ). The A870G polymorphism in Cyclin D1 gene was 
reported to influence differentiation and prognosis in HCC patients (Zhang, Chen et 
al. 2002), In addition, an arginine (Arg)-to-glutamine (Gin) polymorphism at codon 
399 in the XRCCl gene had been proposed to associate with a dose-dependent 
increased risk of early-onset HCC (p=0.01) (Yu, Yang et al. 2003). 
3.1.3 Association of sex steroid related genes and other cancers, like 
prostate cancer 
Here, I reviewed previous studies investigating the association between sex 
steroid related genes and prostate cancer which could be used as a model for my 
study on HCC. 
Inconsistent findings have been reported between SRD5A2 and risk of 
prostate cancer. Ntais et al (Ntais et al. 2003) in 2003, conducted a meta-analysis of 
prostate cancer risk and there SRD5A2 variants: V89L (nine studies), A49T(seven 
studies), and the (TA)n repeat (four studies). The meta-analysis showed that V89L 
(conferring lower enzyme activity) was not associated with overall prostate cancer 
risk but that A49T (conferring higher enzyme activity) and the (TA) „ repeat 
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(supposed to influence mRNA stability) may have modest effects. Although higher 
SRD5A2 activity was reported in African-American men and has been hypothesized 
to contribute to the ethnic differences in prostate cancer risk (Wu et al. 2001), a 
recent study found no associations between V89L and prostate cancer in this 
high-risk population (Sarma et al. 2008). 
In 2002，Chang et.al suggested that a missense SNP (B1-N367T) in 
HSD3B1 was weakly associated with prostate cancer risk (P=0.03), but the joint 
effect of both HSD3B1 and HSD3B2 was significantly associated with prostate 
cancer (P=0.004) (Chang et al. 2002). Subsequently, Parker et.al reported in 2007 
that, the HSD3B1 367Thr allele was positively associated with prostate cancer 
among white men with family history of prostate cancer (odds ratio 3.0，95% 
confidence interval 1.0 to 9.2) although he did not find main effect of HSD3B1 alone 
with prostate cancer (Park, Tanner et al. 2007). 
The AKR1C3 homozygous variant genotypes (c.l5G/Aand c.90 G/A) was 
associated with a decreased risk of benign prostatic hyperplasia (BPH) and prostate 
cancer in a multivariate analyses (HR=0.56, 95% CI=0.35-0.90, HR=0.57, 95% 
CI=0.33-0.98) (Roberts, Bergstralh et al. 2006). This association has to been further 
evaluated by further replication studies. 
Five studies have investigated the role of CYP19A1 polymorphisms in 
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prostate cancer (Latil et al. 2001; Modugno et al. 2001; Suzuki et al. 2003) (Fukatsu 
et al. 2004; Li et al. 2004). Two studies reported a positive association with the 
tetra-nucleotide repeats in intron 4 (Latil, Azzouzi et al. 2001; Suzuki, Nakazato et al. 
2003). Other three studies reported different polymorphisms in associations with 
prostate cancer (Fukatsu, Hirokawa et al. 2004; Li, Cicek et al. 2004; Modugno, 
Weissfeld et al. 2001). 
3.1.4 Aims of the study (Part B) 
As serum level of sex hormones have been associated with various clinical 
diseases such as prostate cancer (Hsing, Reichardt et al. 2002; Severi, Morris et al. 
2006), breast cancer (Key, Appleby et al. 2002), and liver cancer (Kuper, Mantzoros 
et al. 2001), genetic factors or polymorphisms that lead to variations in sex hormone 
levels between individuals may also be associated with HCC. Therefore, it forms an 
objective of this part of the study. 
Epidemiology studies indicated that the incidence rate of HCC in men is 
higher than that in women, and male predominance of hepatitis B virus related HCC 
was associated with serum androgen levels (Yu & Chen 1993). However, although 
androgen levels are believed to be influenced by genetic factors, there is no 
information to indicate which genetic variations in the androgen metabolic pathway 
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are associated with the risk of hepatocellular carcinoma (HCC) development. 
Therefore, in this project, mainly single nucleotide polyporphisms (SNPs) 
of sex steroid related candidate genes were studied for their association with HCC. 
Knowledge of the predisposition genes and alleles for sex steroid levels 
will facilitate better predictor and diagnosis in sex steroid level related diseases. 
Finding predisposition genes for HCC will elucidate pathogenesis of development of 
HCC, and enable patients with higher risks to be more frequently monitoring and 
screening and be diagnosed at an early stage of HCC. 
Hypothesis: Genetic polymorphisms in the sex steroid metabolic pathway 
are associated the risk of HCC. 
Specific objectives: l.To evaluate the linkage disequilibrium (LD) and 
population haploblock structure among SNPs in the candidate genes involved in sex 
steroid metabolism and identify tagging SNPs for studies in the Southern Chinese 
population. 2. To identify the genetic association between haplotypes in these genes 
and risk of HCC in the Chinese population. 
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3.2 Materials and method 
3.2.1 Study subjects, Genomic DNA extraction 
HCC case sample: 290 male HBV-related HCC patients 
HBV controls: 105 male chronic HBV carries 
Population control: 1883 Chinese men with available blood samples (as 
mentioned in chapter 2) 
Informed consents were obtained from all participants. All the patients 
were confirmed to be HCC with histopathological diagnosis. Blood samples were 
obtained by venipuncture, and genomic DNA was extracted from the peripheral 
lymphocytes using commercial DNA extraction kit and followed manufacturer's 
instruction (Roche, U.S.). 
3.2.2 Tissue specimen and cell lines 
The SRD5A1 and SRD5A2 liver expression study included 16 HBV 
related HCC patients. All the study tissues were surgical resection specimens, which 
were confirmed with histopathological diagnosis. Paired tumor and surrounding 
nontumor regions were analyzed in each patient. All patients underwent hepatic 
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resection in Prince of Wales Hospital, Hong Kong. Informed consent was obtained 
from all patients. 
The 22RV-1 human prostate cell lines and Huh7 human liver cell lines 
were routinely grown in RPMI 1640 and DMEMF-12, respectively, and were 
supplemented with 10% FCS，at 37°C in a humidified atmosphere of 5% CO2 in air. 
Cells with a narrow range of passage number (22RV-1, 18-20，Huh7, 20-21) were 
used for SRD5A1 and SRD5A2 mRNA expression study. 
3.2.3 TagSNP selection 
Please refer to 2.2.2 
3.2.4 Genotyping of tagging SNPs 
Please refer to 2.2.3. Selected tagSNPs of genes involved in sex steroid 
pathway were shown in Table 3,2.4.1. 
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Table 3.2.4.1 Genes and tagSNPs selected for the HCC association study 
Gene ^ Gene SNP 
SRD5A1 rs248807 AKR1C3 rs4881400 
rsll738248 rsl1252940 
rs824811 AKRIDI rsll982192 
SRD5A2 rs3731586 rs2306845 
rsl2470143 AKR1C4 rsl334473 
HSD17B2 rsl 364286 rsl7134607 






Genotype distributions of candidate genes polymorphisms were assessed 
for deviations by Hardy-Weinberg Equilibrium (HWE) with test. Logistic 
regression test was used to determine associations of genotypes with case-control 
status. Control groups were divided into HBV-positive control group (105 male HBV 
carriers) and population control group (MrOs). Haploview analysis was used to 
determine haplotype association between case and control group. All statistical 
analyses were carried out using SPSS 15 for Windows (SPSS Inc., Chicago, IL, 
USA), and results were two tailed and conducted at the 5% significance level. 
Generalized multifactor dimensionality reduction (version 0.7; Department 
of Psychiatry and Neurobehavioral Sciences, University of Virginia, Charlottesville, 
VA; http://www.healthsvstem.virginia.edu/intemet/addiction-genomics/softwareA) 
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was used to determine gene-gene interaction on the basis of the work of Lou et al 
(Lou et al. 2007). We determine statistical significance by comparing the average 
prediction error from the observed data with the distribution of average prediction 
errors under the null hypothesis of absence of association derived empirically form 
5000 permutations. The null hypothesis was rejected when the P value derived form 
the permutation test was 0.05 or lower. 
3.2.6 Extraction ofRNA and Reverse-Transcription-PCR 
For PGR studies of SRD5A1 and SRD5A2 mRNA expression, fresh tumor 
and non-tumor samples were collected during surgical resection which were 
immediately frozen and stored at -80°C until RNA extraction process. RNA was 
extracted from tissues and cell lines using TRIzol reagent (Invitrogen, US) and 
reverse transcription kit (ABI high fidelity cDNA synthesis kit). Aliquots of RNA 
were used for cDNA synthesis and then subjected to semiquantitative PCR analysis. 
The amount of cDNA was quantified and normalized by using ^ -actin as control. 
The conditions used for SRD5A1, SRD5A2, and /3 -actin amplification were shown 
in Table 3,2.6.1. 
All PCR products were analyzed by electrophoresis on 2% agarose gel, and 
then photographed for analysis. 
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Table 3丄6丄 Sequence of SRD5A1 and SRD5A2 Primers and PGR conditions 
Gene Forward Primer Reverse Primer Size AT Cycle 
name (bp) (°C) numbers 
SRD5A1 TCTAATAGGTTTTGGCTTGTGG ATAAGCCTCCCCTTGGTATTT 120 57.4 30 
SRD5A2 GGTTTAGCTTGGGTGTCTTCTT TGTGGAATCCTGTAGCTGATTT \\() 63 30,40 
/3-actin AATAGGCACCAGGGCGTGATGGT GCCCAAACATGATCTGGGTCATC • 63 30 
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3.3 Results 
The observed distribution of genotypes was equal to the expected 
distribution under the assumption of Hardy-Weinberg equilibrium. 
3.3.1 SRD5A1 
3.3.L1 SRD5A1 polymorphisms and risk of HCC 
Table 3.3,1.1 and Table 3,3.1.2 show the SRD5A1 polymorphisms and risk 
of HCC compared with both population control group and HBV-positive group. 
Genotype rsl 1738248 was observed to be significantly associated with risk 
of HCC using both population control group and HBV-positive control groups as 
controls (p =0.016，0.004, respectively). In addition, the heterozygous CT genotype 
in rsl 1738248 appeared to be a risk genotype for the development of HCC with OR 
1.48 (95%CI=1.13-1.94) when compared with population control group, and with 
OR 2.55 (95%CI=1.45-4.50) when compared with HBV-positive control group. 
When both heterozygote and homozygote of the T allele were pooled, the Odds ratio 
(OR) for HCC were 1.42 (95% CI=1.10-1.87) and 2.54 (95%CI=1.46-4.43), 
respectively. 
Genotype rs248807 also was observed to be have marginally significant p 
values (p=0.083, 0.076，respectively) when compared with both control groups. 
However, no association with rs824811 and risk of HCC was observed. 
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Table 3.3,1.1.1 Association of variants in SRD5A1 with risk of HCC between 
population control and HCC case patients 
SRD5A1 Cases (%) Controls (%) Odds ratio P value 
(N=271) (N=1822) (95% CI) 
rs248807 (C/A) 
HWE P=0.56 
CC 184(67.9) 1110(60.9) Reference 0.083 
CA 77(28.4) 619(34.0) *0.75 (0.57-0.99) 
AA 10 (3.7) 93 (5.1) 0.59 (0.30-10.14) 
rsll738248(C/T) (N=278) (N=1552) 
HWE P=0.12 
CC 175 (62.9) 1100(70.9) Reference 0.016 
CT 98 (35.3) 417(26.9) *1.48 (1.13-1.94) 
TT 5(1.8) 35 (2.3) 0.89 (0.35-2.32) 
rs824811 (C/T) (N=273) (N=1551) 
HWE=0.22 
CC 3 (1.1) 20(1.3) - 0.802 
CT 51 (18.7) 314(20.2) -
TT 219(80.2) 1217(78.5) -
Note: * The odds ratio is significantly different form l.The OR of rsl 1738248 
geneotype (CT, TT) Vs CC was 1.42 (95% CI=1.10-1.87). 
131 
Table 3.3.LL2 Association of variants in SRD5A1 with risk of HCC among HBV 
positive control and HCC case patients 
SRD5A1 Cases (o/o) Controls (%) Odds ratio P value 
(N=271) (N=101) (95% CI) 
rs248807 (C/A) 
HWE P=0.45 
CC 184(67.9) 56 (55.4) Reference 0.076 
CA 77 (28.4) 41 (40.6) *0.57 (0.35-0.93) 
AA 10(3.7) 4 (4.0) 0.76 (0.23-2.52) 
rsll738248(C/T) (N=278) (N=101) 
HWE P=0.33 
CC 175 (62.9) 82 (81.2) Reference 0.004 
CT 98 (35.3) 18 (15.5) *2.55 (1.45-4.50) 
TT 5(1.8) 1 (1.0) 2.34 (0.27-20.38) 
rs824811 (C/T) (N=273) (N=101) 
HWE=0.46 
CC 3(1.1) 2 (2.0) - 0.802 
CT 51 (18.7) 15(14.9) -
TT 219(80.2) 84 (83.2) -
Note: * The odds ratio is significantly different form l.The OR ofrsll738248 
genotype (CT, TT) Vs CC was 2.54 (95%CI=1.46-4.43). 
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3J,L2 Haplotype analysis 
Three haplotypes accounted for the majority of population chromosome for 
the three SNPs on SRD5A1 gene. The C-C-T haplotype accounted for 51.4% while 
A-C-T haplotype accounted for 21.5% and C-T-T haplotype accounted for 16.1% of 
all haplotypes. (Table i.5.7.2VThe frequency C-T-T haplotype was significantly 
different between case and population control group (p=0.042, after permutation test). 
The C-T-T haplotype appeared to be a risk haplotype for the development of HCC, 
and the odds ratio (OR) for the C-T-T haplotype carrier was 1.33 
(95%CI=1.06-1.66). 
Table 3.3.1.2 Haplotype association of the SRD5A1 gene and risk of HCC (case 
vs.population control group) 
SRD5A1 Case Control Overall P P value OR 
(rs248807& frequency frequency frequency value after (95% CI) 
rsll738248 (N=542) (N=3102) permutation 
&rs824811) 
C-C-T 0.523 0.508 0.514 NS NS Reference 
A-C-T 0.177 0.222 0.215 0.018 0.058 0.82 
(0.61-1.01) 
C-T-T 0.195 0.157 0.161 0.012 0.042 *1.33 
(1.06-1.66) 
Haplotypes are composed with three SNPs (rs248807&rsll738248&rs824811) in the 
SRD5A1 gene. Haploview 4.1 was used to infer haplotypes using an accelerated 
expectation maximization algorithm. 
* The odds ratio is significantly different from 1. 
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3.3.2 SRD5A2 
3,3.2.1 SRD5A2 polymorphisms and risk of HCC 
Table 3.3,2.1 and Table 3.3.2.2 show the SRD5A2 polymorphisms and risk 
of HCC compared with both population control group and HBV-positive group. 
Genotype rs523349 (V89L) frequency was observed to be significantly 
different in HCC patients and population control group (p =0.021). The homozygous 
GG genotype in rs523349 appeared to be a protective genotype for the risk of HCC 
with OR 0.64 (95%CI=0.44-0.93). However, no association was observed between 
HCC patients and HBV-positive control group. 
Table 3J.2.1.1 Association of variants in SRD5A2 with risk of HCC among 
population control and HCC case patients 
SRD5A2 Cases (%) Controls (%) Odds ratio P value 
(N=276) (N=1563) (95% CI) 
rs3731586 (A/G) 
HWE P=0.23 
GG 2 (0.7) 10(0.6) 1.14(0.25-5.23) 0.978 
AG 50(18.1) 278 (17.8) 1.02 (0.73-1.43) 
AA 224 (81.2) 1275 (81.6) Reference 
rsl2470143(C/T) (N=270) (N=1539) 
HWE P=0.29 
CC 105 (38.9) 707 (45.9) 0.81 (0.53-1.24) 0.088 
CT 132(48.9) 652 (42.4) 1.10(0.73-1.67) 
TT 33 (12.2) 180 (11.7) Reference 
rs523349 (V89L) (N=283) (N=1561) 
(C/G) 
HWE=0.98 
GG 66(23.3) 493 (31.6) *0.64 (0.44-0.93) 0.021 
CG 152 (53.7) 758 (48.6) 0.96 (0.70-1.32) 
CC 65 (23.0) 310(19.9) Reference 
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Table 3.3,5.1.2 Association of variants in CYP19A1 with risk of HCC among HBV 
positive control and HCC case patients 
SRD5A2 Cases (o/o) Controls (%) Odds ratio P value 
(N=276) (N=103) (95% CI) 
rs3731586 (A/G) 
HWE P=0.51 
GG 2 (0.7) 2(1.9) 0.40(0.06-2.89) 0.148 
AG 50(18.1) 11 (10.7) 1.83(0.91-3.67) 
AA 224 (81.2) 90(87.4) Reference 
rsl2470143(C/T) (N=270) (N=96) 
HWE P=0.24 
CC 105 (38.9) 39(40.6) 0.49(0.19-1.26) 0.27 
CT 132 (48.9) 51 (53.1) 0.47(0.19-1.19) 
TT 33 (12.2) 6(6.3) Reference 
rs523349 (V89L) (C/G) (N=283) (N=103) 
HWE=0.61 
GG 66 (23.3) 31 (30.1) 0.56(0.28-1.10) 0.24 
CG 152 (53.7) 55 (53.4) 0.72(0.39-1.33) 
CC 65 (23.0) 17(16.5) Reference 
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3.3.2.2 Haplotype analysis 
Two common haplotypes were found in the population composing of the 3 
SNPs of SRD5A2 gene. The A-C-G haplotype and A-T-C haplotype account for 
nearly 90% of all haplotypes (Table 3,3,1.2). The frequency of A-C-G haplotype was 
significantly different between case and population control group (p=0.032), and 
A-C-G haplotype appeared to be a protective haplotype for the risk of HCC. 
However, after permutation test for multiple comparisons, no association was found 
between A-C-G haplotype and the risk of HCC. 
Table 3.3.2.2 Haplotype association of the SRD5A2 gene and risk of HCC (case 
vs.population control group) 
SRD5A2 Case Control Overall P P value after 
frequency frequency frequency value permutation 
(N=540) (N=3078) 
A-C-G 0.505 0.544 0.546 0.032 NS 
A-T-C 0.366 0.325 0.331 0.054 NS 
G-C-C 0.104 0.095 0.096 0.500 NS 
A-C-C 0.025 0.022 0.270 NS 
Haplotypes are composed with 3 SNPs (rs3731586, rsl2470143 and rs523349) in the 
SRD5A2 gene. Haploview 4.1 was used to infer haplotypes using an accelerated 
expectation maximization algorithm. 
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3.3.4 HSD17B2 
33,3,1 HSD3B1 polymorphisms and risk of HCC 
Table 33,3.LI and Table 3.3,3.L2 show the HSD3B1 polymorphisms and 
risk of HCC compared with both population control group and HBV-positive group. 
Compared with both control groups, the genotype frequencies of both 
SNPs on HSD3B1 show no significant difference. No associations between HSD3B1 
and risk of HCC were observed. 
Table 3.3 J. 1.1 Association of variants in HSD3B1 with risk of HCC among 
population control and HCC case patients 
HSD3B1 Cases (o/o) Controls (%) Odds ratio P value 
(N=281) (N=1548) (95% CI) 
rsl2022215(A/C) 
HWE P=0.28 
CC 13 (4.6) 54 (3.5) 1.38(0.74-2.58) 0.56 
AC 93 (33.1) 493 (31.8) 1.08(0.82-1.42) 
AA 175 (62.3) 1001 (64.7) Reference 
rs879332(C/T) 
HWE P=0.65 (N=275) (N=1815) 
CC 51 (18.5) 398 (21.9) 0.94(0.64-1.38) 0.16 
CT 155 (56.4) 911 (50.2) 1.25(0.92-1.69) 
TT 69 (25.1) 506 (27.9) Reference 
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Table 3.3,5.1.2 Association of variants in CYP19A1 with risk of HCC among HBV 
positive control and HCC case patients 
HSD3B1 Cases (%) Controls (%) Odds ratio P value 
(N=281) (N=102) (95% CI) 
rsl2022215(A/C) 
HWE P=0.12 
CC 13 (4.6) 4(3.9) 1.26(0.39-4.01) 0.73 
AC 93 (33.1) 30(29.4) 1.21(0.73-1.98) 
AA 175 (62.3) 68(66.7) Reference 
rs879332(C/T) (N=275) (N=102) 
HWE P=0.54 
CC 51 (18.5) 13 (12.7) 1.54(0.72-3.26) 0.41 
CT 155 (56.4) 62 (60.8) 0.98(0.57-1.67) 
TT 69 (25.1) 27(26.5) Reference 
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3 . 3 . 2 . 2 Haplotype analysis 
Three common haplotypes were composed by 2 SNPs on HSD3B1 gene. 
The C-A haplotype accounts for nearly 46.7% while the T-A haplotype accounts for 
33.6% of all haplotypes (Table 3.3.1,2). No association was found between HSD3B1 
haplotype and risk of HCC. 
Table 3.3.2.2 Haplotype association of the HSD3B1 gene and risk of HCC (case 
vs.population control group) 
HSD3B1 Case Control Overall P P value 
(rsl2022215&rs879332) frequency frequency frequency value after 
(N=550) (N=3096) permutation 
C-A 0.470 0.466 0.467 0.888 NS 
T-A 0.319 0.339 0.336 0.337 NS 
TX 0.210 0.190 0.193 0.262 NS 
Haplotypes are composed with 2 SNPs (rsl2022215 and rs879332) in the HSD3B1 




3,3,4,1 HSDl 7B2 polymorphisms and risk of HCC 
Table 3.3.4.1.1 and Table 3JJJ.2 showed the HSD17B2 polymorphisms 
and risk of HCC compared with both population control group and HBV-positive 
group. 
No significant genotype differences were observed between HCC patients 
and both population and HBV positive control. 
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Table 3.3,5.1.2 Association of variants in CYP19A1 with risk of HCC among HBV 
p o s i t i v e control and HCC case patients 
HSD17B2 Cases (%) Controls (%) Odds ratio P value 
(N=279) (N=1555) (95% CI) 
rsl364286(A/G) 
HWE P=0.11 
GG 56 (20.1) 286(18.4) 1.04 (0.72-1.50) 0.63 
AG 136(48.7) 805 (51.8) 0.90 (0.67-1.20) 
AA 87(31.2) 464 (29.8) Reference 
rs2966241(A/G) (N=271) (N=1547) 
HWE P=0.41 
GG 5 (1.8) 15 (1.0) 1.84 (0.66-5.09) 0.15 
AG 38 (14.0) 277(17.9) 0.76 (0.52-1.09) 
AA 228 (84.1) 1255 (84.1) Reference 
rs2955162(A/G) (N=281) (N=1836) 
HWE P=0.71 
GG 230(81.9) 1513 (82.4) Reference 0.40 
AG 45 (16.0) 314(17.1) 1.04(0.74-1.46) 
AA 6(2.1) 9(0.5) 1.06 (0.85-1.57) 
rsl364283(C/A)(N=275) (N=1532) 
HWE P=0.49 
CC 89(32.4) 503 (32.8) 0.80 (0.56-1.15) 0.27 
CT 127 (46.2) 761 (49.7) 0.76 (0.54-1.06) 
TT 59 (21.5) 268 (17.5) Reference 
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Table 3.3,4.1.1 Association of variants in HSD17B2 and risk of HCC among HBV 
positive control and HCC case patients 
HSD17B2 Cases (o/o) Controls (%) Odds ratio P value 
(N=279) (N=101) (95% CI) 
rsl364286(A/G) 
HWE P=0.23 
GG 56 (20.1) 25 (24.8) 0.93 (0.50-1.70) 0.28 
AG 136 (48.7) 40(39.6) 1.41 (0.83-2.38) 
AA 87 (31.2) 36 (35.6) Reference 
rs2966241(A/G) (N=271) (N=102) 
HWE P=0.31 
GG 5 (1.8) 1 (1.0) 1.84 (0.21-15.09) 0.70 
AG 38(14.0) 17(16.7) 0.82 (0.44-1.54) 
AA 228 (84.1) 84 (82.4) Reference 
rs2955162(A/G) (N=281) (N=98) 
HWE P=0.25 
GG 230 (81.9) 81 (82.7) Reference 0.82 
AG 45 (16.0) 14(14.3) 0.62 (0.14-2.78) 
AA 6(2.1) 3(3.1) 0.70 (0.17-2.86) 
rsl364283(C/A)(N=275) (N=99) 
HWE P=0.77 
CC 89 (32.4) 32 (32.3) 0.71 (0.35-1.42) 0.36 
CT 127 (46.2) 52 (52.5) 0.62 (0.32-1.19) 
TT 59 (21.5) 15(15.2) Reference 
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3,3.4,2 Haplotype analysis 
Eight common haplotypes were composed by four SNPs on HSD17B2 gene. 
The A-A-G-A, A-G-G-C and A-A-G-C haplotypes account for nearly 80% of all 
haplotypes (Table 33.4,2). No association was found between HSD17B2 haplotype 
and risk of HCC. 
Table 3.3.4.2 Haplotype association of the HSD17B2 gene and risk of HCC (case 
vs.population control group) 
HSD17B2 Case Control Overall P P value 
(rs2966241 & rsl364286 frequency frequency frequency value after 
& rs2955162 & rsl364283) (N=542) (N=3064) permutation 
A-A-G-A 0.359 0.345 0.347 0.502 NS 
A-G-G-C 0.240 0.235 0.236 0.811 NS 
A-A-G-C 0.193 0.212 0.209 0.309 NS 
G-G-G-C 0.080 0.087 0.086 0.563 NS 
A-G-A-A 0.054 0.046 0.047 0.361 NS 
A-G-A-C 0.044 0.044 0.044 0.997 NS 
A-G-G-A 0.021 0.020 0.02 0.932 NS 
G-G-G-A 0.010 0.012 0.012 0.636 NS 
Haplotypes are composed with 4 SNPs (rs2966241, rsl364286, rs2655162, 
rsl364283) in the HSD17B2 gene. Haploview 4.1 was used to infer haplotypes using 
an accelerated expectation maximization algorithm. 
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3.3.5 CYP19A1 
3.3,5.1 CYP19A1 polymorphisms and risk of HCC 
Table 3,3,5,1,1 and Table 3.3.5,1,2 show the CYP19A1 polymorphisms and 
risk of HCC compared with both population control group and HBV-positive group. 
Compared with both control groups, the genotype frequencies of both 
SNPs on CYP19A1 show no significant difference. No associations between CYP19 
and risk of HCC were observed. 
Table 33,5.1,1 Association of variants in CYP19A1 with risk of HCC among 
population control and HCC case patients 
CYP19A1 Cases (o/o) Controls (%) Odds ratio P value 
(N=281) (N=1795) (95% CI) 
rs2470152(C/T) 
HWE P=0.54 
CC 72 (25.6) 453 (25.3) 1.04 (0.73-1.49) 0.97 
CT 140(49.8) 889(49.5) 1.03 (0.76-1.41) 
TT 69 (24.6) 453 (25.2) Reference 
rs2899470(G/T) (N=280) (N=1852) 
HWE P=0.68 
GG 122 (43.6) 867 (46.8) 0.86 (0.56-1.30) 0.59 
GT 126 (45.0) 790 (42.7) 0.97 (0.64-1.48) 
TT 32(11.4) 195 (10.5) Reference 
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Table 3.3,5.1.2 Association of variants in CYP19A1 with risk of HCC among HBV 
positive control and HCC case patients 
CYP19A1 Cases (%) Controls (%) Odds ratio P value 
(N=281) (N=101) (95% CI) 
rs2470152(C/T) 
HWE P=0.23 
CC 72 (25.6) 19(18.8) 1.76 (0.91-3.39) 0.24 
CT 140(49.8) 50(49.5) 1.30 (0.76-2.20) 
TT 69(24.6) 32 (31.7) Reference 
rs2899470(G/T)(N=280) (N=100) 
HWE P=0.75 
GG 122 (43.6) 41 (41.0) 0.93 (0.42-2.06) 0.78 
GT 126 (45.0) 49(49.0) 0.80 (0.37-1.76) 
TT 32(11.4) 10(10.0) Reference 
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3.3.2.2 Haplotype analysis 
Three haplotypes were prevalent in the population, which is composed of 2 
SNPs of CYP19A1 gene. The C-G and T-T haplotype account for nearly 80% of all 
haplotypes (Table 3,3,5,2). No association was found between CYP19A1 haplotype 
and risk of HCC. 
Table 3.3.5.2 Haplotype association of the CYP19A1 gene and risk of HCC (case 
vs.population control group) 
CYP19A1 Case Control Overall P P value 
(rs2470152&rs2899470) frequency frequency frequency value after 
(N=560) (N=3590) permutation 
C-G 0.472 0.469 0.469 0.891 NS 
T-T 0.307 0.290 0.292 0.398 NS 
T-G 0.188 0.214 0.210 0.158 NS 
^ 0.033 0.028 0.029 0.465 NS 
Haplotypes are composed with 2 SNPs (rs2470152 and rs2899470) in the CYP19A1 




3.3.6.1 AKR1C4 polymorphisms and risk of HCC 
Table 3,3.6,1.1 and Table 3.3.6.L2 show the AKR1C4 polymorphisms and 
risk of HCC compared with both population control group and HBV-positive group. 
Compared with both control groups, the genotype frequencies of both 
SNPs on AKR1C4 show no significant difference. No associations between AKR1C4 
and risk of HCC were observed. 
Table 3J,6.1.1 Association of variants in AKR1C4 with risk of HCC among 
population control and HCC case patients 
AKR1C4 Cases (%) Controls (%) Odds ratio P value 
(N=235) (N=1533) (95% CI) 
rsl334473 (C/T) 
HWE P=0.96 
CC 127 (54.0) 856 (55.8) 0.74 (0.44-1.26) 0.54 
CT 89(37.9) 582(38.0) 0.77 (0.45-1.31) 
TT 19(8.1) 95 (6.2) Reference 
rsl7134607 (A/G) (N=260) (N=1561) 
HWE P=0.55 
GG 204 (78.5) 1228 (78.7) Reference 0.22 
AG 49(18.8) 313 (20.1) 1.03 (0.90-5.56) 
AA 7 (2.7) 20(1.3) 2.08 (0.88-5.00) 
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Table 3.3.6.1.2 Association of variants in AKRl C4 with risk of HCC among HBV 
positive control and HCC case patients 
AKR1C4 Cases (%) Controls (%) Odds ratio P value 
(N=235) (N=99) (95% CI) 
rsl334473 (C/T) 
HWE P=0.78 
CC 127 (54.0) 50 (50.5) 1.20 (0.51-2.83) 0.83 
CT 89 (37.9) 40 (40.4) 1.05 (0.44-2.53) 
TT 19(8.1) 9(9.1) Reference 
rsl7134607 (A/G) (N=260) (N=103) 
HWE P=0.23 
GG 204 (78.5) 86 (83.5) Reference 0.82 
AG 49(18.8) 17(16.5) 1.21 (0.66-2.23) 
AA 7 (2.7) 0(0.0) -
3,3.6.2 Haplotype analysis 
Three common haplotypes were composed by two SNPs of AKR1C4 gene. 
The C-G haplotype accounts for more than 60% of all haplotypes (Table 3.3,6,2). No 
association was found between AKRl C4 haplotype and risk of HCC. 
Table 3.3.6,2 Haplotype association of the AKR1C4 gene and risk of HCC (case 
vs.population control group) 
AKR1C4 Case Control Overall P P value 
(rsl334473&rsl7134607) frequency frequency frequency value after 
(N=470) (N=3066) permutation 
C-G 0.621 0.635 0.633 0.547 NS 
T-G 0.269 0.252 0.255 0.420 NS 
^ 0.110 0.113 0.112 0.849 NS 
Haplotypes are composed with 2 SNPs (rsl334473 and rsl7134607) in the AKR1C4 




3,3,7,1 AKRIDI polymorphisms and risk of HCC 
Table 3.3,7,1.1 and Table 3.3.7.1.2 show the AKRIDI polymorphisms and 
risk of HCC compared with both population control group and HBV-positive group. 
Compared with both control groups, the genotype frequencies of both 
SNPs on AKRIDI show no significant difference. We could observe no associations 
between AKRIDI and risk of HCC. 
Table 3.3,7, LI Association of variants in AKRIDI with risk of HCC among 
population control and HCC case patients 
AKRIDI Cases (%) Controls (%) Odds ratio P value 
(95% CI) 
rsll982192(G/T) (N=274) (N=1487) 
HWE P=0.38 
GG 17(6.2) 95 (6.4) 1.01 (0.59-1.74) 0.75 
GT 109 (39.8) 556 (37.4) 1.11 (0.85-1.45) 
TT 148 (54.0) 836 (56.2) Reference 
rs2306845(G/T)(N=236) (N=1495) 
HWE P=0.29 
GG 159(67.4) 995 (66.6) Reference 0.48 
GT 71 (30.1) 437 (29.2) 0.58 (0.20-1.41) 
TT 6 (2.5) 63 (4.2) 0.60 (0.25-2.56) 
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Table 3.3,5.1.2 Association of variants in CYP19A1 with risk of HCC among HBV 
positive control and HCC case patients 
AKRlDl Cases (o/o) Controls (%) Odds ratio P value 
(N=274) (N=101) (95% CI) 
rsll982192(G/T) 
HWE P=0.11 
GG 17(6.2) 6 (5.9) 0.91 (0.34-2.38) 0.84 
GT 109 (39.8) 37(36.6) 0.87 (0.71-1.87) 
TT 148 (54.0) 58 (57.4) Reference 
rs2306845(G/T) (N=236) (N=100) 
HWE P=0.74 
GG 159(67.4) 65 (65.0) Reference 0.91 
GT 71 (30.1) 32 (32.0) 0.91 (0.21-3.85) 
TT 6 (2.5) 3 (3.0) 0.82 (0.20-3.33) 
3.3.7.2 Haplotype analysis 
Three common haplotypes were composed by two SNPs on AKRIDI gene. 
The G-T and G-G haplotype account for more than80% of all haplotypes (Table 
3.3,7.2). There were no significant difference in haplotype frequencies between case 
and population control group. No association was found between AKRIDI 
haplotypes and risk of HCC. 
Table 3.3,7.2 Haplotype association of the AKRIDI gene and risk of HCC (case 
vs.population control group) 
AKRIDI Case Control Overall P P value 
(rs2306845&rsll982192) frequency frequency frequency value after 
(N=472) (N=2974) permutation 
G-T 0.560 0.560 0.560 0.997 NS 
G-G 0.260 0.251 0.253 0.676 NS 
T ^ 0.179 0.187 0.186 0.665 NS 
Haplotypes are composed with 2 SNPs (rs2306845 and rsl 1982192) in the AKRIDI 
gene. Haploview 4.1 was used to infer haplotypes using an accelerated expectation 
maximization algorithm. 
150 
3.3.8 AKRl C3 
33.8.1 AKR1C3 polymorphisms and risk of HCC 
Table 3.3,8.1.1 and Table 3.3.8.1,2 show the AKR1C3 polymorphisms and 
risk of HCC compared with both population control group and HBV-positive group. 
The genotype frequencies of both SNPs on AKRl C3 show no significant 
difference between case and both control groups. No associations between AKRl C3 
and risk of HCC were observed. 
Table 3J.8.1.1 Association of variants in AKR1C3 with risk of HCC among 
population control and HCC case patients 
AKR1C3 Cases (%) Controls (%) Odds ratio P value 
(N=264) (N=1525) (95% CI) 
rs4881400(G/T) 
HWE P=0.63 
GG 118 (44.7) 630(41.3) 1.05 (0.70-1.59) 0.52 
GT 111 (42.0) 698 (45.8) 0.90 (0.59-1.35) 
TT 35 (13.3) 197(12.9) Reference 
rsll252940(A/T) (N=268) (N=1547) 
HWE P=0.18 
TT 11 (4.1) 96 (6.2) 0.64 (0.34-1.23) 0.40 
AT 92 (34.5) 532 (34.4) 0.97 (0.74-1.28) 
AA 165 (61.4) 919 (59.4) Reference 
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Table 3,3.8,L2 Association of variants in AKR1C3 with risk of HCC among HBV 
positive control and HCC case patients 
AKR1C3 Cases (%) Controls (%) Odds ratio P value 
(N=264) (N=94) (95% CI) 
rs4881400(G/T) 
HWE P=0.21 
GG 118 (44.7) 37(39.4) 1.46 (0.73-2.93) 0.55 
GT 111 (42.0) 41 (43.6) 1.24 (0.62-2.47) 
TT 35 (13.3) 16(17.0) Reference 
rsll252940(A/T) (N=268) (N=102) 
HWE P=0.79 
TT 11(4.1) 8 (7.8) 0.46 (0.18-1.21) 0.23 
AT 92 (34.5) 39 (38.2) 0.79 (0.49-1.28) 
AA 165 (61.4) 55 (53.9) Reference 
3.3.8.2 Haplotype analysis 
Three possible haplotypes were composed by two SNPs on AKR1C3 gene. 
The G-A and T-T haplotypes account for more than 80% of all haplotypes (Table 
3,3,8,2). There were no significant difference in haplotype frequencies between case 
and population control group. No association was found between AKR1C3 
haplotypes composed by rs4881400 and rsll252940 and risk of HCC. 
Table 3.3,8.2 Haplotype association of the AKR1C3 gene and risk of HCC (case 
vs.population control group) 
AKR1C3 Case Control Overall P P value 
(rs4881400&rsll252940) frequency frequency frequency value after 
(N=528) (N=3050) permutation 
GA 0.647 0.616 0.621 0.176 NS 
TT 0.199 0.214 0.211 0.431 NS 
TA 0.140 0.148 0.147 0.603 NS 
CT 0.015 0.022 0.021 0.288 NS 
Haplotypes are composed with 2 SNPs (rs4881400 and rs 11252940) in the AKR1C3 
gene. Haploview 4.1 was used to infer haplotypes using an accelerated expectation 
maximization algorithm. 
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3.3.9 mRNA expression study of the 5 a -reductase isoforms 
3.3.9.1 Expression ofSRDSAl and SRD5A2 mRNA in HCC patients 
Expression of SRD5A1 and SRD5A2 mRNA in tumor tissues and the 
surrounding nontumor tissues were investigated by RT-PCR in HBV positive HCC 
patients (n=16). As shown in Fisure 3.3.9.1, the expression of SRD5A1 and 
SRD5A2 mRNA was detected in nearly all the tissue samples assayed, both 
nontumor (NT) and tumor (T) tissues. -actin was shown as house keeping gene. 
Overall, SRD5Alwas expressed at higher level in both T tissues and NT tissues, 
suggesting that SRD5A1 is the preferentially expressed 5 a -reductase isoform in 
liver tissue. 
Non-Tumor tissue (NT) Tumor tissue (T) 
SRD5A1 m m H H i ^ m m i m ^ ^ i 
*SRD5A2 l ^ H ^ H ^ ^ B I ^ ^ H B B H I K E B ^ ^ H H 
3-ac t i n B o g m ^ g B j g g g g m 
Fieure 3.3.9.1 SRD5A1 (30 cycles of PCR) and SRD5A2 (40 cycles of PCR) mRNA 
expression in human HCC tissues. 
NT represents adjacent non-tumor liver tissue and T represents paired HCC tissues 
collected from the same patients. 
* The SRD5A2 mRNA expression was not detected in 30 cycles PCR. 
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3.3.9,2 Expression ofSRDSAl and SRD5A2 mRNA in prostate and HCC cell lines 
SRD5A1 and SRD5A2 expression was also studied in the 22RV-1 human 
prostate cancer cell lines and Huh7 human HCC cell lines by RT-PCR. As shown in 
Fieure 3.3.9,2. both cell lines expressed SRD5A1 and SRD5A2 mRNAs, while 
SRD5A2 mRNA expression was weaker in Huh7 HCC cell lines compared with its 
intensity in 22RV-1 human prostate cancer cell lines. 
22RV-1 Prostate Huh7 liver 22RV-1 Prostate Huh7 liver 
cancer cancer cancer cancer 
SRD5A1 (30 cycles of PCR) SRD5A2 (40 cycles of PCR) 
Figure3.3.9,2 SRD5A1 and SRD5A2 mRNA expression in prostate cancer and HCC 
cell lines. 
3.3.10 Overall association of polymorphisms in sex steroid 
metabolism genes and risk of HCC 
Table 3.3,10.1 showed the overall association of polymorphisms in sex 
steroid metabolism genes and risk of HCC. It was observed that only SRD5A1 
polymorphisms passed all statistical tests and were significantly associated with risk 
of HCC. 
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Table 3.3.10.1 Overall association of polymorphisms in sex steroid metabolism 
genes and risk of HCC 
P value 
Haplotype 
, . Case-HBV association 
Gene Case-population . . 
, positive control between case and 
control group 
group control group 
(permutation) 
SRD5A1 0.016 0.004 0.042 
SRD5A2 0.021 NS NS 
HSD3B1 NS NS NS 
HSD17B2 NS NS NS 
AKR1C4 NS NS • NS 
AKRIDI NS NS NS 
AKR1C3 NS NS NS 
CYP19A1 ^ ^ NS 
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3.3.11 GMDR analysis 
Table 3J.11 shows the results of rsl 1738248 (SRD5Al)and rs523349 
(V89L) (SRD5A2), rsl 1738248 (SRD5A1) and rs2899470 (CYP19A1) interactions 
in HCC case group compared with HBV-positive control group. One two-locus 
model (rsl 1738248 vs. rs523349) had a minimum prediction error of 40.4% 
(p=0.003) and a maximum CV consistency of 9 of 10. The other two-locus model 
(rsll738248 vs. rs2899470) had a minimum prediction error of 42.6% (p=0.025) and 
a maximum CV consistency of 5 of 10. These two models were shown in Fimre 
3.3.11.1 and Fisure 3.3,11.2.1 was able to classify that the combination of CC in 
rsl 1738248 with GG and CG in rs523349 (V89L) as the low risk group, and others 
as high risk group. In addition, it was found that the combination of CC in 
rsl 1738248 with all genotypes in rs2899470 could be attributed as low risk group, 
while others were classified with high risk group. However, when I do GMDR 
analysis between HCC case group and population control group, no gene-gene 
interactions were found, (data not shown) 
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Table 3,3,11 two-loci interaction models by GMDR analysis* 
Two locus model Cross-validation Prediction error P value based on 5000 
consistency (%) permutations 
rsl 1738248, 9 40.4 0.003 
rs523349 (V89L) 
rsl 1738248， 5 42.6 0.025 
rs2899470 
*Note: Another SNP rs248807 on SRD5A1 was also included into GMDR analysis 
but found no interaction with other two SNPs. 
rs11738248(C/T) 
C C C T T T 
• -18.3 
^ O to.5 • 
^ ^2.9 
O fp. 24.5 • 
% o I I 




• • I l l i l • 姊 
Fieure 3JJL1 2 loci model for rsl 1738248 and rs523349 interaction between HCC 
case group and HBV positive control group. 
High risk genotypes were in dark and low risk genotypes were in grey. The figures 
above the bars (left bars represented HCC case group while right bars were HBV 
positive control group) were score numbers. 
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rs11738248 (C/T) 
CC CT T T 
-24.8 
— O • • 114 ^ ^ 
O • • • 二 0-3 Q.0 
一 -29.2 
g H ^ • 
芸 ① • • 11.0 
§ 1 1 m 1 . 1 
CNJ 画 — . _ 
h I 二 • I 这 
Figure 3.3.11.2 2 loci model for rsll738248 and rs2899470 interaction between 
HCC case group and HBV positive control group. 
High risk genotypes were in dark and low risk genotypes were in grey. The figures 
above the bars (left bars represented HCC case group while right bars were HBV 
positive control group) were score numbers. The white box represented unclassified 
group due to lacking such kind of combination. 
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3.4 Discussion 
Male predominance in HCC has been suggested both in animal model and 
in clinical studies. It was observed that in animal models, male mice with HBx 
infection were more likely to develop HCC than their female counterpart and the 
castration reduced the tumor incidence in carcinogen induced liver cancer (Kim, 
Koike et al. 1991; Lindhe, Porsch-Hallstrom et al. 1990; Moriya, Fujie et al. 1998; 
Vesselinovitch, Itze et al. 1980), indicating that androgen may serve as a cancer 
promoter in the development of HCC. 
In addition, in clinical studies, high serum T has been demonstrated to be associated 
with risk of HCC in some studies (Yu & Chen 1993; Yu，Cheng et al. 2000b; Yuan, 
Ross et al. 1995). The positive association between serum T level and HCC incidence 
rate raise the possibility that genes involved in sex steroid metabolic pathway may 
exert an influence on the etiology of HCC. 
3.4.1 5 a -reductase and risk of HCC 
This study found that compared with population control group, SNP 
rsl 1738248 on SRD5A1 was significantly associated with risk of HCC, and this 
association still existed when compared with HBV positive control group. Another 
SNP on the same gene, rs248807, also marginally significantly associated with HCC 
development. The C-T-T haplotype constructed by three SNPs on SRD5A1 
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(rs248807, rsl 1738248 and rs824811) could be a risk haplotype for HCC etiology. In 
addition, it was also observed that rs523349 (V89L) on SRD5A2 appeared to have a 
relationship with risk of HCC. 
SRD5A1 and SRD5A2 are two genes encoding 2 different isoforms of 5 a 
-reductase that could convert T to its more potent biological form, DHT. In tissue 
expression study, it was reported that SRD5A1 was found largely in non reproductive 
tissues such as skin and liver, while SRD5A2 is located predominantly in the male 
reproductive tissues including seminal vesicles, epididymis, and prostate (Thigpen, 
Silver et al. 1993).Studies focused on SRD5A2 V89L polymorphisms found distinct 
results among different ethnic groups. Some studies suggested that SRD5A2 
polymorphisms were statistically associated with risk of HCC among Asian people 
(Sung, Tang et al. 2003; Yu, Yang et al. 2001). On the other hand, a study among 
Italian population observed no such association (Rossi, Leveri et al. 2003). 
3J,U SRD5A2 
The valine to leucine substitution at codon 89 on SRX)5A2 appeared to be 
common in Asian compared with whites or African-Americans (Makridakis, Ross et 
al. 1997). It was reported that there was a significant association between SRD5A2 
V89L polymorphisms and 5 a -reductase activity in vivo, with VV homozygous ( CC 
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genotype) having higher enzyme activity compared with VL (CG genotype) and LL 
(GG genotype) homozygous (Makridakis, Ross et al. 1997). In this study which 
compared the HBV positive HCC and population control group in Chinese men, it 
was found that SRD5A2 V89L polymorphisms were significantly associated with 
risk of HCC, with allele dosage effect. However, other SNPs that were selected on 
the same gene did not show any association with risk of HCC. In SRD5A2 mRNA 
expression study, it was observed that SRD5A2 mRNA was expressed at a low level 
in liver tissue, which was relatively activated in tumor tissues compared with the 
surrounding nontumor tissues, indicating that SRD5A2 may be associated with HCC 
development. This result, together with other reports, suggested that SRD5A2 
polymorphisms could play a role in the predisposition to HBV related HCC in some 
subgroup of Asian population and V89L allele may be the primarily functional allele 
accounting for elevated risk of HCC in such subgroup. 
3J.L2SRD5A1 
SRD5A1 polymorphisms have been suggested to be associated with 
various kinds of sex steroid related disease, such as male pattern baldness (Ellis et al. 
1998)，benign prostate hyperplasia (BPH) (Klotsman et al. 2004), polycystic ovary 
syndrome (PCOS) (Goodarzi et al. 2006). However, there were lack of reports about 
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whether SRD5A1 polymorphisms were in relation with HCC, a presumably 
androgen related disease. 
Three intronic SNPs on SRD5A1 were studied, and the SNP rsll738248 
was found to be significantly associated with risk of HCC. In addition, the C-T-T 
haplotype appeared to be a risk haplotype for the HCC development. In SRD5A1 
mRNA expression study, we found that SRD5A1 was also highly expressed in liver 
tissue and its expression level was activated in tumor tissue compared with its 
surroundings. The result served as an indicator for SRD5A1 association with HCC. 
To the best of my knowledge, this is the first association study between SRD5A1 
gene polymorphisms and risk of HCC. Polymorphisms in introns may affect splicing 
and thus influence the protein function. However, functional studies have not been 
performed to examine the outcome of associated SNPs or haplotypes. Whether these 
three SNPs are in LD with another cSNP or they exert functional effect on 5 a 
-reductase activity has not yet been known. 
3.4.2 Other genes and association with HCC 
3.4.2.1 HSD17B2 and risk of HCC 
Distributed among many extraglandular tissues and liver, the 17/5 -HSD 
type 2 isozyme catalyzes both the inactive C19-steroid androstenedione to the 
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biologically active androgen, testosterone (Moghrabi, Hughes et al. 1998), and 
estradiol to estrone (Olson, Bandera et al. 2007). 
Many studies on HSD17B2 gene have focused on its relationship with 
breast cancer risk (Jansson et al. 2007; Olson, Bandera et al. 2007). However, No 
genetic association study have been carried out to detect relationship between 
HSD17B2 polymorphisms and risk of HCC. 
This study involved four intronic SNPs on HSD17B2 gene to represent 
genetic variation in the whole CHB population. No SNP was significantly associated 
with risk of HCC. 
3,4.2,2 HSD3B1’ AKR1C3, AKR1C4’ AKRIDI and risk of HCC 
No association was found between HSD3B1, AKR1C3, AKR1C4, 
AKRIDI polymorphisms and risk of HCC both in population and HBV-positive 
control group. There is also a lack of reports about such associations in previous 
studies. However, the possible associations between these genes and risk of HCC 
may still exist as AKR1C3, AKR1C4 and AKRIDI are genes that mainly expressed 
in liver tissue and play important roles in sex steroid metabolic pathway. The results 
of PART A study of the genetic determinants of circulating sex steroid concentrations 
also indicated that they did not have strong effect on steady state steroid level except 
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AKR1C4. In this study, tagSNPs on these genes were studied. It is still possible that 
some unknown isolated functional alleles may exert an influence on enzyme activity. 
Further studies involve larger sample size and more SNPs would be required to 
explore associations for such SNPs might be not in LD with common SNPs. 
3,4,23 CYP19A1 and risk of HCC 
Previous study have pointed out that the relationship between aromatase 
(CYP19A1) enzyme activity and the development of HCC, and also suggested that 
the use of anti-aromatase agents may be an alternative way for the treatment of HCC 
(Agarwal, Takayama et al. 1998; Castagnetta, Agostara et al. 2003; Yabuuchi, 
Kawata et al. 1993). However, in this study involving Chinese men, no such 
associations were observed in both control groups. This may be accounted for the 
heterogeneity among different ethnic groups. Although a significant association 
between CYP19A1 haplotypes composed by two SNPs (rs2470152 and rs2899470) 
and E2 level or E2/T ratio, but not T or FAI, was observed, the association between 
CYP19A1 polymorphisms and risk of HCC could not be identified. The reason 
account for this may be that although CYP19A1 polymorphisms could be a predictor 
for E2 level or E2/T ratio, the E2 level may not be a direct carcinogen for the 
development of HCC. 
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3.4.3 Gene-Gene interactions associated with HCC 
By using GMDR analysis, this study suggested significant gene-gene 
interactions between SRD5A1 and SRD5A2, SRD5A1 and CYP19A1. Previous 
studies suggested that elevated testosterone was associated with risk of HCC (Yu et 
al. 2000a; Yu & Chen 1993; Yu, Cheng et al. 2000b), and enzymes that play 
important roles in sex steroid metabolisms may contribute to risk of HCC. SRD5A1 
and SRD5A2 are two genes that encoding 5 a -reductase which could convert 
testosterone to its more potent biological form, 5a-DHT. In addition, CYP19A1 
encoding enzyme aromatase also exert influence on the estrogen and androgen 
conversion. Since both major loci effect and polygenic influence may contribute to 
the development of HCC, a multi-loci approach should be used to analyze the 
quantitative traits of HCC. It was observed that people with combinations of T allele 
in rsl 1738248 (SRD5A1) (which was associated with low DHT) and C allele in 
rs523349 (V89L) (SRD5A2) were more susceptible to HCC. The gene-gene 
interaction between SRD5A1 and SRD5A2 for risk of HCC suggested that these 
genes might have interaction on in the androgen pathways that influence HCC 
development. In addition, it also showed that there might be some interactions 
between SRD5A1 and CYP19A1 but the interaction was as strong as that between 
SRD5A1 and SRD5A2. 
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Chapter 4 Conclusions and prospect for future work 
4.1 Conclusion 
Diseases have been associated with sex steroid levels, such as prostate 
cancer, breast cancer, and androgenic alopecia. It is believed that genes involved in 
sex steroid metabolic pathway could be associated with serum sex steroid levels 
which in turn, lead to various kinds of disease. However, relationship between gene 
polymorphisms and sex steroid levels were not well characterized and different 
results had been reported in various ethnic groups. 
HCC is the commonest primary cancer of the liver. HCC incidence is 
increasing in recent years and it has become the fifth commonest malignant tumor all 
over the world. However, the pathogenesis of HCC is not yet well defined. It is 
believed that HCC is a complex disease caused by the combination effects of gene 
and environment. HCC male predominance has been observed and it is speculated 
that sex steroids, especially androgen, may play a role in the carcinogenesis of HCC 
and genes involved in sex steroid metabolic pathway may be associated with risk of 
HCC. 
In the part A study of this project, I have investigated polymorphisms in 
genes involved in sex steroid metabolic pathway and their associations with sex 
steroid levels. Previous studies have indicated the association between SRX)5A1, 
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SRD5A2, CYP19A1 polymorphisms and sex steroid levels. In this study, 5 
additional genes (HSD17B2, HSD3B1, AKR1C3, AKR1C4 and AKRIDI) were also 
investigated, which also played indispensable role in sex steroid metabolisms. The 
results suggested that CYP19A1，SRD5A1 and AKR1C4 polymorphisms could 
affect serum sex steroid levels among individuals. 
In the part B study, genes involved in sex steroid metabolic pathway (listed 
above) were also investigated to identify relationship with risk of HCC. V89L on 
SRD5A2 has been reported to be associated with risk of HCC in Asian population. In 
this study, this association was replicated in Chinese men. In addition, a new 
association was found that the SNP rsll738248 in SRD5A1 was significantly 
associated with risk of HCC. A risk haplotype C-T-T constructed by three SNPs on 
SRD5A1 (rs248807, rsl 1738248 and rs824811) was also identified. These findings 
singled out that 5 a -reductase, among other enzymes in the pathway, might play an 
important role in the development of HCC. 
Combining with these two parts of study together, the C-T-T haplotype on 
SRD5A1 was observed to be associated with low serum DHT level and appeared to 
be risk haplotype for development of HCC. In SRD5A1 mRNA expression study, it 
was shown that SRD5A1 was mainly expressed in liver, and its expression level was 
activated in tumor tissue compared with its surroundings. Therefore, it was 
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speculated that the C-T-T haplotype might be in relation to low serum DHT level and 
appeared to be risk haplotype for development of HCC. The paradoxical observations 
may be related to several possibilities. One is that involvement of non-androgen 
receptor pathways in HCC pathogenesis might enhance conversion rate from T to 
DHT. The second is that differential effect across age group as the subjects in Part A 
were older than HCC patients. The third is Gene-gene interaction effect as explained 
in next paragraph. 
As for SRD5A2, it was found SRD5A2 V89L was significantly associated 
with risk of HCC. However, such association with SRD5A2 fell short of significance 
in further haplotype analysis. In addition, the GMDR analysis suggested that the 
gene-gene interaction between SRD5A1 and SRD5A2 might have interacting 
pathways that influence HCC development. Therefore, the pathogenesis of HCC may 
be consequence of combination interaction effects of the two genes (SRD5A1 and 
SRD5A2). 
There were two hypotheses about the development of HCC. One is that 
high exposure to testosterone in liver tissue due to a high circulating testosterone 
level as a result of an enhanced production in gonads. In this hypothesis, SRD5A2 
might play a key role as it is primarily expressed in the gonads. The other is that 
local signal transduction within the liver cell plays an important role. Since SRD5A1 
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is primarily expressed in hepatocytes, it would be more important in the second 
hypothesis. 
In my study, the latter theory was supported, as we found that SRD5A1 was in 
strong associations with risk of HCC, and that SRD5A1 was mainly expressed in 
liver tissue compared with SRD5A2. Therefore, we proposed that the carcinogenesis 
of T might be largely associated with local effect of androgen in liver tissue. 
4.2 Future works and prospect 
The genetic association studies on sex steroid levels and risk of HCC 
provide new insight to the pathogenesis of HCC. Genetic polymorphisms of the 5 a 
-reductase were indicated to play an important role in both predicting sex steroid 
levels and HCC pathogenesis. Other candidate genes also showed significant 
associations either with sex steroid levels or risk of HCC. However, as we have not 
measured androgen concentrations in HCC patients, the association between 
androgen levels in HCC tissues and risk of HCC are good topics for future studies. In 
addition, the underlying mechanisms are still unknown. Therefore, functional studies 
on these candidate genes involved in sex steroid pathway are indispensable for 
elucidating the carcinogenesis of sex steroids in the HCC development in the future. 
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